The role of ephrinB2 in blood vessel development. by Foo, S.S.C.
The Role of EphrinB2 in Blood 
Vessel Development
Shane Siang Chin Foo
September, 2004
Thesis presented in fulfilment of the degree of Doctor of 
Philosophy at the University of London
Vascular Development Laboratory, Cancer Research UK, London 
Department of Anatomy, University College London
1
UMI Number: U602792
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U602792
Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
To my family
2
Acknowledgements
I sincerely thank all those people who have helped me throughout my four years at 
Cancer Research UK. I have had a wonderful and productive time at the Institute, which 
was made all the more pleasurable by the people that I’ve had the good fortune to meet 
and work with.
First and foremost I wish to thank my supervisor Dr. Ralf Adams allowing me the 
privilege to untake my PhD in his laboratory and all that he has done for me during my 
time here. Thanks to all members of the Vascular Development Laboratory who have 
made it a great place to work. In particular, I am indebted to Amelia Compagni and 
Vassiliki Kostourou for their guidance, support, encouragement and insightful 
discussions throughout the course of my PhD as well as the writing of the thesis. 
Special thanks to Tim Schmidt, Cristina Roca, Per Lindblom and Christopher Turner 
from the lab for being fantastic colleagues as well as being great friends. I am grateful 
for Nnennaya Kanu for the correction of the thesis as well as being on the same 
wavelength as me.
I deeply thank my mother Boon Too Foo and my brother Willy Siang Wei Foo for their 
unconditional love, for being the pillars of my life and for their endless support. I show 
great appreciation to Fui Luh Fung for her love that makes life more enjoyable and 
easier for me especially through moments of desperation.
3
Abstract
The development of the vascular network is a complex process that is controlled by 
precisely balanced angiogenic and anti-angiogenic factors. Several studies have 
established that ephrinB2 and its receptor EphB4 are important regulators of angiogenic 
remodelling in the embryonic vasculature. The ablation of either gene in mice leads to 
fatal cardiovascular defects and early lethality. As ephrinB2 is expressed in different 
cell types within blood vessels, specifically in arterial endothelial cells, pericytes and 
vascular smooth muscle cells, the function of the molecule in each cell population has 
remained unclear.
To determine the role of ephrinB2 expression in the luminal endothelial lining of blood 
vessels, tissue-specific knockout mice were generated with the Cre-loxP method. The 
resulting mutants displayed fatal defects in the development of blood vessels and the 
heart that resembled the phenotype of the global ephrinB2 null mice. This demonstrated 
that ephrinB2 is essential in the endothelial cells and that its expression in other cell 
types within the cardiovascular system is not sufficient to compensate for this loss. 
Pericytes and vascular smooth muscle cells, so-called mural cells, are associated with 
the endothelium and are essential for the formation of a stable and mature vascular 
network. To study the role of ephrinB2 in mural cells that express progressively 
increasing levels of the ligand during the second half of embryonic development, a 
transgenic mouse line expressing Cre recombinase under the control of a fragment from 
the PDGFRp gene was established. This permitted the generation of mural cell-specific 
ephrinB2 knockouts in which the investment of pericytes and smooth muscle cells in 
the microvasculature was impaired so the vessel wall assembly was defective. 
Consequently, these mutants displayed oedema, haemorrhaging and presumably died of 
respiratory arrest. These findings demonstrate that ephrinB2 expression in mural cells is 
essential for the maturation of the microvessels but apparently not for the remodelling 
of the endothelium.
As insufficient support by mural cells and the resulting increase in blood vessel 
permeability is a relevant factor in human disease, such as diabetic retinopathy and 
tumours, the findings presented here argue that the ligand may be a potential target for 
therapeutic intervention.
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Chapterl I Introduction
Chapterl
In the earliest stages of development, the embryo survives in the absence of the 
vasculature as it initially receives the oxygen and nutrients through diffusion from the 
yolk sac and placenta. However, this is quickly changed due to the increasing demand 
for oxygen and nutrients required for its growth. The embryo then rapidly forms a 
highly vascularised system through two processes known as vasculogenesis and 
angiogenesis (Figurel.l). The resulting mature vascular system ensures that an adequate 
blood flow is maintained to provide the cells of the organism with sufficient supply of 
nutrients and oxygen, as well as the removal of waste and by-products.
1.1 Vasculogenesis
The initial formation of a primitive vascular network in the embryo is established at the 
time when somites begin to form, by a process known as vasculogenesis. The first phase 
of the construction of the embryonic vasculature, begins with the differentiation of 
mesenchymal cells from the lateral plate mesoderm of the yolk sac into haemangioblast, 
which are the precursors of both blood cells and endothelial cells (Shalaby et al., 1997). 
These cells condense into aggregates known as blood islands, of which the inner cells 
become haematopoietic stem cells (blood cells precursors), while the outer cells develop 
into angioblasts (blood vessels precursors). The angioblasts then differentiate in situ and 
assemble into endothelial cell cords, which then extend and fuse together to form 
connecting tubes. These later develop into a capillary network known as the primary 
capillary plexus. While the initial vascular plexa are still emerging, first steps of 
remodelling occur, thus transforming the uniform primary plexa into more complex 
secondary structures.
In the embryo proper, the primitive vascular network includes the major vessels such as 
the aortic arches, the dorsal aorta and the cardinal veins, as well as honeycomb-like 
plexa connecting these principle vessels. While in the yolk sac, the assembly of 
endothelial cells gives rise to the vitelline vein, which allows the delivery of nutrients,
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waste removal and promotes gaseous exchange between the maternal and embryonic 
circulation. Molecules from different growth factor families act in concert to promote 
vasculogenesis. Both vascular endothelial growth factor (VEGF) and transforming 
growth factor p (TGF-P) signalling pathway are found to be required for mesoderm 
differentiation, haematopoiesis and blood vessel formation. VEGF-A and VEGFR2 
(flk-1) knockouts in mice are lethal at E8.5-11 due to defects in angioblast 
differentiation, haematopoiesis and blood vessel formation (Carmeliet et al., 1996; 
Ferrara et al., 1996; Shalaby et al., 1997). In contrast, the lethality in VEGFR1 (flt-1) 
embryos is attributed to the increase of haemangioblast commitment, thereby resulting 
in the formation of disorganized vessels due to overcrowding of the endothelial cells 
(Fong et al., 1999). Both TG F-pi and TGF-P receptor 2 knockouts die at E10.5 due to 
defects in haematopoiesis and vasculogenesis (Dickson et al., 1995; Oshima et al., 
1996), while ALK5 (a subtype of TGF-p receptor 1) knockouts show normal 
haematopoiesis (Larsson et al., 2001). However, they still die at E10.5 and display 
defects in vessel formation in the yolk sac and placenta, which are caused by enhanced 
endothelial cell proliferation, impaired endothelial migration and suppressed fibronectin 
production, in vitro.
1.2 Angiogenesis
The second process, known as angiogenesis, refers to the formation of new blood 
vessels through the modification of pre-existing vascular structures. In this process the 
primary vascular network is remodelled, pruned and enlarged into distinct arteries, 
veins and interconnecting capillary beds that are characteristic of the mature 
vasculature. Angiogenesis is a complex biological process involving the delicate co­
ordination of multiple steps that are controlled by an exquisite balance between 
activating and inhibitory effectors (Figure 1.2).
1.2.1 Intussusception
Angiogenesis is normally thought of as the formation of new capillaries and vessels 
mediated through the sprouting, migration and proliferation of endothelial cells that are
13
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resident in the capillaries, a process coined as sprouting angiogenesis. Nonsprouting 
angiogenesis by means of intussusception is another important process involved in the 
expansion and modification of vessels and capillary formation. It involves the 
partitioning of existing vessel lumens into smaller ones by formation and insertion of 
interstitial tissue structures or pillar tissues into the vessel lumen. This process was first 
observed in the rapidly expanding postnatal lung capillary bed, but has since been 
detected in a variety of tissues and organs in embryonic as well as adult angiogenesis 
(Patan, 2004).
1.2.2 Vasodilation and permeability
The vasodilation of pre-existing vessel is the initial process in angiogenesis and 
involves nitric oxide (NO) (Carmeliet, 2000). Remarkably, vascular endothelial growth 
factor (VEGF) induces NO synthase activity in endothelial cells. The increased levels of 
in tracellu lar NO stim ulate guanyl-cyclase to synthesise cyclic guanoside 
monophosphate (cGMP), which subsequently results in the relaxation of vascular 
smooth muscle cells (vSMCs). VEGF is also involved in increasing vascular 
permeability of endothelial cells through the formation of fenestrae, a process that is 
restricted to the endothelium of glomeruli, gastrointestinal tract, endocrine organs and 
different areas of the brain (Zachary and Gliki, 2001). More generally, vascular 
permeability can be increased by the disruption of cell-to-cell adhesion, caused by the 
phosphorylation of components of intercellular endothelial adherens and tight junctions 
(Zachary and Gliki, 2001). VEGF stimulation leads to the phosphorylation of adhesion 
molecules including vascular endothelial (VE)-cadherin and P-catenin, as well as the 
tyrosine phosphorylation of tight junction molecules, occludin and zona occluden (ZO)- 
1. To a certain extent, this allows plasma proteins from the blood stream, such as 
fibrinogen and plasminogen, to extravasate through inter-endothelial cell junctions into 
the surrounding tissue (Carmeliet, 2000). These plasma proteins then provide temporary 
structural support for the migration of activated endothelial cells.
Control of vascular permeability is not only critical during developmental angiogenesis, 
but also for the normal physiology of the adult vasculature. Excessive vascular leakage 
is a factor in pathological conditions such as intracranial hypertension or circulation
14
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collapse, and therefore blood vessel permeability must be tightly regulated. However, 
the signalling mechanism regulating this effect remains largely obscure.
Angiopoietinl (Angl), is an inhibitor of vascular permeability and is expressed in mural 
cells (consisting of vSMCs and pericytes). Targeted gene inactivation studies have 
revealed its important role in remodelling and promoting stabilisation of the vessels, 
through mediating tight association between endothelial and mural cells, and 
interactions with extracellular matrix molecules. A ngl knockout mice die at 
midgestation (E l2.5) and display cardial defects as well as generalised vascular 
remodelling and branching defects (Suri et al., 1996). Mutant analysis showed a failure 
of myocardial and mural cell recruitment to the vessel wall and aberrant organisation of 
extracellular matrix elements such as collagen fibres. Although not as severe, these 
phenocopy defects seen in knockout mice of the cognate receptor, Tie2, a tyrosine 
kinase expressed in the endothelium (Sato et al., 1995). Mutants lacking Tie2 die at 
E10.5, displaying growth retardation of the heart and defective vascular remodelling. 
Further evidence of Ang-1 association with the regulation of vascular permeability, are 
provided by its overexpression in the skin of transgenic mice under the control of the 
keratin (K)-14 promoter (Suri et al., 1998). These mice display larger, more numerous 
and more highly branched vessels. More interestingly, subsequent studies of these mice 
show that overexpression of Ang-1 makes dermal vessels resistant to the increase in 
permeability (i.e. leakiness) caused by inflammatory agents or by overexpression of 
VEGF (Thurston et al., 1999). Further corroborating data is provided by another study 
using the mouse neonatal retina where the vascular network is formed in the absence of 
mural cells (Uemura et al., 2002). In this setting, the vasculature is poorly remodelled 
and leaky, but the application of Ang-1 is remarkably able to restore a hierarchical order 
of the larger vessels and rescue oedema and haemorrhage. As there are many 
pathologies associated with microvascular leakage, such as inflammatory diseases and 
diabetic retinopathy, Ang-1 has the therapeutic potential to reduce plasma leakage in 
these conditions.
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1.2.3 Vessel destabilisation and matrix degradation
Before the ECs of pre-existing vessels are able to invade out of their resident site, inter- 
endothelial cell contacts must be loosened, mural cells need to detach, the EC basement 
membrane must be degraded and the perivascular extracellular matrix needs to be 
remodelled. A known trigger of such processes is Ang-2, an antagonist of Ang-1, that 
inhibits Tie2 signalling and causes destabilisation of the vessels leading to subsequent 
endothelial cell migration. Proteases, such as the plasminogen activators, chymases, 
matrix metalloproteases (MMP), and Heparanase families, are important effectors in 
these processes as they degrade the matrix molecules and liberate sequestered growth 
factors such as bFGF, VEGF and insulin-like growth factor (IGF)-l from the matrix 
(Conway et al., 2001). MMPs, in particular MMP-2, MMP-3 and MMP-9, play a 
critical role in degrading extracellular matrix and basement membrane structures, 
thereby permitting endothelial migration. Integrin receptors, particularly a v(33, can 
recruit and possible activate MMPs, especially MMP-2, to localised microdomains on 
the cell membranes of blood vessels, where they conduct their proteolytic function 
(Brooks et al., 1996). The recruitment by integrins helps to regulate MMP activity, as 
excessive matrix degradation would impede endothelial invasion. The TGF-|31 
signalling pathway is also implicated in this process. Targeted ablation of one of its type 
I receptors for TGFp, the activin receptor-like kinase (ALK)-l, leads to lethality by 
E10.5 due to severe vascular abnormalities (Oh et al., 2000). The lumen of major blood 
vessels including the dorsal aorta and branchial arches, are highly dilated and the 
capillary vessels are excessively fused. The fact that ALK-1 deficiency leads to 
increased levels of different plasminogen activators as well as Ang-2, suggests that the 
developing blood vessels in the knockouts may have undergone increased perivascular 
proteolysis and are more permeable, thus leading to excessive proliferation of ECs and 
capillary fusion.
1.2.4 Endothelial cell proliferation and migration
Once the physical barriers provided by the basement membrane are dissolved, 
proliferating endothelial cells are free to form sprouts and to migrate to distant sites. A
16
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delicate balance between angiogenic and angiostatic factors controls these processes. 
Proliferating ECs are guided by gradients of chemotactic agents through the 
disintegrated basement membrane into the remodelled perivascular space. These 
processes involved in active angiogenesis are tightly regulated during the development 
of the embryo and adult organism, and are mediated through the interplay between 
various isoforms of VEGF, angiopoietins, fibroblast growth factors (FGFs), ephrins, 
PDGF-B and their respective receptors, as well as many other molecular factors (Table
1.1). VEGF and the angiopoietins appear to be specific mitogens for endothelial cells, 
whereas FGFs induce proliferation in a wide variety of cell types. Several of these 
angiogenic molecules have had their distinct function and contribution revealed through 
the generation of knockout mice, despite considerable molecular redundancies (Table
1.2). Inhibitors of angiogenesis include endostatin, angiostatin and Thrombospondins 
(Table 1.1).
1.2.5 Lumen formation and vessel stabilisation
Once migrating endothelial cells have reached the target area, they assemble into a 
monolayer and form tube-like structures enclosing a lumen. The intercalation of 
endothelial cells and vessel fusion of pre-existing cells enables vessels to increase their 
lumen size and length to meet changing demands. Interestingly, the different isoforms 
of VEGF-A have been shown in vivo to be involved in determining vessel size and 
branching behaviour of the growing microvessel network. Mutant mice that only 
express the solubleVEGF120 isoform, without heparin-binding capabilities, developed 
capillary networks with fewer branch points and larger luminal diameter. In contrast, 
mice solely expressing VEGF188, the heparin-binding isoform, exhibited the formation 
of ectopic and abnormally thin vessel branches, while mutants lacking either VEGF164 
or one of its co-receptors neuropilin (Nrp)-l showed no vascular branching defects. The 
mytocyte enhancer binding factor 2C (MEF2C), as well as the integrins a v(33 and a 5 are 
also involved in lumen formation, whereas Thrombospondin-1 appears to act as an 
inhibitor (Carmeliet, 2000).
Once nascent endothelial tubes are formed, they must be stabilised by mural cells. To 
achieve this, the endothelium secretes factors that cause the mesenchymal cells in the
17
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surrounding tissue to proliferate and migrate to the abluminal surface of the premature 
vessels, in a process known as vascular myogenesis. Then, these primordial mural cells 
differentiate either into pericytes, which are located within the basement membrane, or 
into vSMCs, which are found wrapped around the outer face of the basement membrane 
(Figure 1.3). VSMCs cover the majority of the vascular network but are absent from 
capillaries, while pericytes cover even the smallest capillary branches. There is a 
gradual transition from vSMCs to pericytes on the arterial side of capillaries and then 
back to vSMCs on the venular side.
1.3 Arterial or venous fate, determined by genetic 
predisposition or by haemodynamic force?
It was previously thought that the structural difference between arteries and veins is 
functionally determined by blood flow. Arterial vessels, which receive blood at high 
pressure from the heart, are characteristically surrounded by a thick layer of vSMCs 
(tunica media)(Figure 1.4). Venous vessels, on the other hand, carry efferent circulation 
of lower pressure, thus have less ensheathing smooth muscle, and contain valves to 
prevent blood back-flow (Figure 1.4). There is now a growing body of evidence 
indicating that molecular differences do exist between arterial and venous endothelial 
cells and are predetermined before the onset of blood circulation through genetic 
regulation.
A first key finding, indicative of arterial-venous specific gene expression profiles, was 
that ephrinB2 is specifically expressed in arteries while one of its cognate tyrosine 
kinase receptors, EphB4 is specifically expressed in veins (Wang et al., 1998; Adams et 
al., 1999; Gerety et al., 1999). Ablation of the genes for ephrinB2 or EphB4 in mouse, 
results in lethality, defective remodelling of the yolk sac vascular plexus, decreased 
branching of cranial capillaries, abnormal sprouting of intersomitic vessels and 
decreased vascularisation of the neural tube. In both knockouts, angiogenesis is 
arrested, affecting both arteries and veins. The expression pattern of ephrinB2 and 
EphB4 was determined by the knock-in of the lacZ reporter cassettes into the 
endogenous gene loci. Homozygous embryos (knockouts) still expressed lacZ in
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specific vessels, showing that the respective promoter/enhancer elements are still active 
and that ephrinB2 and EphB4 are not required for the initial specification of arterial and 
venous fate. It is believed that interactions between ephrinB2 and its receptor EphB4 
modulate angiogenesis in two ways. A t the border between arterial and venous 
capillaries the “attractive” interactions might help to ensure that arterial and venous 
capillaries are connected. In non-border regions, they may ensure that the fusion of 
capillaries to make larger vessels respects arterial-venous identity possibly through 
repulsive signals (Yancopoulos et al., 1998).
Gridlock, a basic-helix-loop-helix (bHLH) transcription factor, is an early determinant 
for arterial specification. Angioblasts expressing gridlock in the lateral posterior 
mesoderm, favour differentiation into an arterial cell fate (Zhong et al., 2000). 
Interestingly, the removal of gridlock expression in zebrafish, by genetic mutations or 
morpholino-mediated gene knockdown, ablates some arteries and leads to an expansion 
of the venous domain, as determined by diminution of ephrinB2 expression and 
increase in EphB4-positive structures (Zhong et al., 2001). Furthermore, gridlock has 
been shown to be downstream of Notch, as interference with Notch signaling using 
blocking agents reduces arterial and increases venous domains, similar to what has been 
observed for gridlock mutants. Notch signalling is associated with cell fate 
determination in various cell types and for the definition of tissue boundaries (Zhong et 
al., 2001). Inhibition of Notch in zebrafish leads to the loss or arterial markers including 
ephrinB2 and ectopic expression of venous markers. Mice lacking Notch 1, one of four 
Notch receptors known in mammals, display vascular defects with disruption at the 
anterior bifurcation of the aorta (Krebs et al., 2000; Lawson et al., 2001). More recently, 
it has been reported that VEGF acts downstream of sonic hedgehog (Shh) and upstream 
of the Notch pathway to control the determination of arterial cell fate in zebrafish 
(Lawson et al., 2002). The loss of either VEGF or Shh leads to the loss of arterial 
identity, i.e. ephrin-B2a expression, while their overexpression resulted in ectopic 
expression of arterial markers. Furthermore, arterial differentiation was rescued in 
embryos lacking Shh activity by injection of VEGF mRNA. Likewise, defective VEGF 
signalling was rescued by activation of the Notch pathway. Genetic studies in mice 
lacking the expression of the Notch ligands Delta-like (Dll)-4 (arterial endothelium 
specific) or Jagged 1 (endothelium specific), revealed critical roles in angiogenic 
remodelling in the yolk sac and in the embryo but their involvement in vessel identity is
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unclear ((Xue et al., 1999) and unpubished data from Mailhos et al.). However, 
mutations in the Notch signalling pathways has been linked to several human 
syndromes that display vascular defects. Mutations in the Notch3 gene causes cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL), a hereditary adult-onset condition causing stroke and vascular dementia 
(Joutel et al., 1996). Mutations in the Jagged (Jag)-l gene causes Alagille syndrome, 
which is a developmental disorder characterised by abnormalities in multiple organs 
including the liver, heart, eye, and kidneys (Li et al., 1997).
The TGF(3 signalling pathway has been also shown to be important in the regulation of 
arterial-venous identity. The human vascular disease called Hereditary Haemorrhagic 
Telangiectasia (HHT), is caused by the loss or normal arterial-venous distinction, 
leading to vascular malformations that subsequently result in haemorrhaging, shunting 
and emboli. Genetic studies have established that HHT is caused by mutations in both 
ALK1 and the TGF|3 co-receptor endoglin (Azuma, 2000). Genetic targeting of these 
genes has shown that they are essential for the functional and molecular distinction 
between arteries and veins (Urness et al., 2000; Sorensen et al., 2003). Both knockouts 
die by E l 1.5 with severe arteriovenous malformations resulting from fusion of major 
arteries and veins as well as shunting between presumptive arterial and venous vascular 
beds. The arterial specific marker, ephrinB2 was downregulated. Mutant embryos 
showed the loss of functional identity as intravascular haematopoietic clusters, which 
are normally restricted to arterial vessels, developed ectopically in veins.
In contrast to the concept of genetically controlled vessel fates, there are several 
emerging studies in the chick and quail that challenge this notion by showing that 
arterial-venous differentiation is controlled by haemodynamic forces. Two studies 
address whether endothelial cells are committed to an arterial or venous fate once 
expressing their specific markers (Moyon et al., 2001; Othman-Hassan et al., 2001). In 
quail embryos, ECs were isolated from either arteries or veins, which were 
characterised by the expression of markers (ephrinB2 and neuropilin-1 for the arteries, 
Tie2 for the veins). Tissue pieces were then grafted into chick embryos and it was later 
analysed whether quail cells from veins had contributed to arteries or veins. The results 
reveal that endothelial cells of either arterial or venous origin are able to switch to the
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other arterial or venous identity and adopt their respective new marker expression. This 
was dependent on the embryonic stage of the quail cells as older ones were unable to 
switch but respected the arterial-venous identity of the chick vessels. These findings 
indicate that there is some level of plasticity in the determination of vessel fate and the 
adoption of the new vessel identity could be mediated through local cues (such as 
vSMC interaction), blood flow, or blood pressure related signals in the endothelial cells. 
Another study, using time-lapse video-microscopy to follow the formation of the 
vasculature of the chick yolk sac in real-time, provided evidence that haemodynamic 
flow mediates arterial-venous differentiation and patterning (le Noble et al., 2004). It 
was shown that to form a mature vascular network consisting of paired and interlacing 
arterial-venous patterns, thin vessels from the arterial domain of the yolk sac must be 
disconnected from the arterial tree and reconnected to the venous system. This implies 
that endothelial plasticity is necessary to fashion normal growth of veins. To test the 
role of haemodynamic flow, the direction of blood flow in the developing vasculature 
was experimentally altered. This led to the reprogramming of the arterial-venous pattern 
suggesting that haemodynamic flow is a main regulator of yolk sac vascular 
development. However, in some areas of undifferentiated capillary beds of the yolk sac 
with disrupted blood flow, ephrinB2 expression was detected, which is inconsistent 
with genetically predetermined expression in the absence of haemodynamic factors.
At this point, one can conclude that the development of arterial-venous identity involves 
an intricate interplay between genetic regulation and haemodynamic forces, each of 
which contributes a certain level of plasticity. The precise mechanism of how this 
arterial-venous fate is established and whether one of the two contributing factors is 
prevalent remains to be uncovered.
1.4 Interactions between mural cells and endothelial cells
Besides stabilising the vessels by inhibiting endothelial proliferation and migration, and 
by stimulating the production of extracellular matrix, mural cells protect the newly 
formed vessel from rupture and regression and play an important role in haemostatic 
control. Larger vessels become covered by additional muscular coatings that provide 
additional elastic and vascomotor properties necessary to accommodate increased blood
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flow (Figure 1.4). This process is also influenced by mural cell-mediated deposition of 
elastin fibres and extracellular components. Once the final shape of the vessel is 
established, mural cells mediate many specialised functions in vascular beds. They 
control haemostasis, provide a blood barrier and scavenge plasma molecules that pass 
through the endothelium, regulate vascular permeability in the glomerulus, and control 
vessel remodelling and plasticity (Carmeliet and Collen, 2000). An example of the 
ability of vSMCs to adapt to specialised functions, are the mesangial cells in kidney 
glomeruli. Mesangial cells control the intussusception of capillaries in the glomerulus 
and thereby increase the surface area for filtration of the blood.
1.5 Molecules involved in mural cell differentiation, 
recruitment, growth, and remodelling
The origin of smooth muscle cells is very complex and depends on their location. 
Smooth muscle cell differentiation can occur by the following: 1) differentiation of 
mesodermal cells through differentiation signals secreted by the endothelium; 2) 
transdifferentiation of ECs into vSMCs or of bone marrow precursors and macrophages 
triggered by the autocrine release of angiopoietin-1; 3) transformation of epicardial cells 
to coronary smooth muscle; and 4) differentiation of the mesectoderm of the neural 
crest into vSMC (Berk, 2001). The complexity of the origin of vSMC suggests that 
growth factors and their receptors may control vSMC differentiation and growth in 
different vascular beds. Smooth muscle differentiation involves transcriptional events 
mediated by the serum response factor, Prx-1 and Prx-2, CRP2/SmLIM , capsulin, and 
members of the Hox, MEF2 and GATA family, which are not reviewed here (see 
(Gittenberger-de Groot et al., 1999)).
In terms of molecular mechanisms that regulate interactions between mural cells and 
ECs, at least four pathways are found to be involved. Key molecular components of 
these include (a) Ang-1 and Tie2; (b) platelet-derived growth factor B (PDGF-B) and 
PDGF receptor p (PDGFRJ3); (c) sphingosine-1-phosphate-1 (S1P1) and endothelial 
differentiation sphingolipid G-protein-coupled receptor 1(EDG1); and (d) transforming
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growth factor (TGF)-P (Jain, 2003). Other molecules contributing to mural cell 
differentiation and recruitment include heparin binding EGF-like factor (HBEGF), 
Endothelin-1 and the Eph/ephrin system (Berk, 2001).
Of the factors mentioned above, PDGF-B and TGF-P have been studied in most detail. 
Besides stimulating differentiation of SMC from mesoderm, both are also involved in 
vSMC recruitment to the vessel wall. PDGF-B, which is produced by immature 
endothelial cells, can induce mesenchymal cell proliferation and migration towards the 
endothelial cells in vitro  (Hirschi et al., 1999). Its essential role in mural cell 
recruitment has been demonstrated in vivo through the generation of knockout mice 
lacking PDGF-B or its cognate receptor, PDGFR-p. Both mutants display similar 
vascular defects and pericyte loss (Soriano, 1994; Lindahl et al., 1997; Hellstrom et al., 
1999). The cytokine TGF-|31 can inhibit the activities of other angiogenic factors in EC 
proliferation and migration, but can also induce vessel maturation by stimulating 
extracellular matrix production and mural cell differentiation. Co-culture systems of 
mesenchymal and endothelial cells led to TGF-P 1 activation and the induction of 
pericyte/vSMC differentiation (Hirschi et al., 1998; Darland and D'Amore, 2001). At 
the same time, endothelial cell proliferation and migration becomes inhibited (Sato et 
al., 1990). TGF-P 1 is expressed in multiple cell types including mural cells and ECs, 
and its pro- or anti-angiogenic role is determined by the context and its concentration. 
Low concentrations were found to synergistically enhance angiogenesis, induced by 
factors such as VEGF and bFGF, while high concentrations were inhibitory (Jain, 
2003). The role of TGF-P in the control of mural cell-EC interactions, has been 
demonstrated by genetic studies in mice. Target gene inactivation of the TGF-p receptor 
ALK-1 has led to embryonic lethality at E10.5 due to vascular defects caused by 
improper differentiation and recruitment of vSMC to blood vessels (Oh et al., 2000). 
Knockout mice for TGF-P 1, the type II ALK-5, the co-receptor endoglin, and 
downstream signalling molecules such as Smad5, have revealed the contribution of 
these molecules to the initial phases of angiogenesis as well as vessel maturation 
(Carmeliet, 2000).
Besides molecular regulators, mentioned above, local physical factors such as hypoxia, 
mechanical forces, injury and flow dynamics control the recruitment of mural cells.
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Despite our knowledge of many relevant signalling receptors and interacting molecules, 
the overall mechanism by which mural cells exert their multiple functions with 
endothelial cells in vivo is not well defined. Open questions include the in-depth 
knowledge of the mechanism of mural cell recruitment, how endothelial tubes are 
ensheathed, how they differentiate to serve local functions and the role of local 
extracellular matrix and endothelium. Acquiring thorough knowledge of such processes 
may provide the basis for therapeutic approaches.
1.6 The super family of receptor tyrosine kinases
Receptor tyrosine kinases (RTKs) have been recognised as critical mediators of 
numerous morphogenic processes during embryonic development. They also play 
essential roles during blood vessel development and its maturation. Examples are the 
vascular endothelial growth factor receptor (VEGFR), Tie, platelet derived growth 
factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) and Eph receptors 
(Risau and Flamme, 1995; Gale and Yancopoulos, 1999). Some of these molecules and 
their ligands regulate vasculogenesis and different aspects of angiogenesis including the 
recruitment of mural cells and the associated remodelling of extracellular matrix. The 
roles of PDGF-B/PDGFRp and Eph/ephrin are reviewed here while the well 
characterised VEGF/VEGFR and angiopoeitin/Tie-2 receptor families are reviewed 
elsewhere (see (Daniel and Abrahamson, 2000; Yancopoulos et al., 2000)).
1.7 Eph/ephrin gene family
The function of Ephs and ephrins have predominately been studied in the nervous 
system, where they are involved in patterning of the rhombomeres in the hindbrain, in 
axon pathfinding, and the guidance of migrating neural crest cells (Flanagan and 
Vanderhaeghen, 1998). More recently, Eph receptor and their ligands have emerged as 
important mediators of vascular growth and development.
The Eph receptors, with 14 members, constitute the largest class of RTKs identified. 
The first receptor was named for its expression in an erythropoietin-producing
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hepatocellular (Eph) carcinoma cell line from which it was first isolated. Their 
respective family of binding ligands was termed “ephrin” (Eph receptor interacting 
molecules)(EN Committee, 1997) and consists of 8 members. Both Eph receptors and 
ephrins are divided into two subclasses, class A and B, on the basis of binding 
specificity and structure. In general, EphA receptors (EphAl-8) promiscuously bind to 
ephrinA  ligands (ep h rinA l-5 ) ,  which are attached to the cell by a 
glycosylphosphotidylinositol (GPI) anchor. EphB receptors (EphBl-6) interact with 
ephrinB ligands (ephrinBl-3) contain a hydrophobic transmembrane region and a 
highly conserved short cytoplasmic domain. There are some members that have binding 
affinities for both classes of molecules such as EphA4, capable of ephrinB2 and 
ephrinB3 binding, and ephrinB 1, capable of binding to EphA2. The interaction of Eph 
receptors with cell surface-bound ephrins makes them unique because other families of 
RTKs bind to soluble ligands. Furthermore, Eph-ephrin interactions mediate bi­
directional signalling, whereby signal transduction pathways are activated downstream 
of ligands as well as receptors.
1.7.1 Structure of Eph receptors
Similar to other RTKs, Eph receptors contain a single transmembrane domain. The 
extracellular region consists of a highly conserved globular ligand binding domain, 
made up of immunoglobulin-like motifs, followed by a cysteine-rich domain and two 
fibronectin type III repeats (Figurel.5). The structural difference in the ligand-binding 
domain, dictates the specific binding affinities to either ephrin A or B class ligands. 
Fibronectin type III repeats may be involved in receptor dimerisation and/or interactions 
with other proteins such as NMDA receptors (Dalva et al., 2000). The intracellular 
region consists of a juxtamembrane region, a conserved tyrosine kinase domain, a 
sterile-a-motif (SAM) domain, and a PSD95/Dlg/Z01 (PDZ)-binding motif. The 
function of the conserved Eph SAM domain remains elusive, as its deletion does not 
impair EphA4 function in vivo (Kullander et al., 2001). However, structural studies 
have revealed its potential involvement in modulating receptor dimerisation and 
clustering (Stapleton et al., 1999; Thanos et al., 1999), or even bind adapter proteins 
(Boyd and Lackmann, 2001).
25
Chapterl
1.7.2 Signalling Mechanism Through Eph receptors
Based on structural studies, it is thought that unbound ephrins cluster together to form 
homodimers, which subsequently bind to Eph receptors with a 1:1 stoichiometry. Upon 
ligand and receptor binding, they must reorient themselves and adopt the required active 
conformation to initiate signalling into both interacting cells. Crystallographic studies of 
the EphB2-ephrinB2 complex have revealed a unique mode of ligand-receptor 
recognition where two receptors bind two ligand molecules to form a ring 
heterotetramer complex, which fix the orientation of participating ligands and receptors 
((Himanen et al., 2001), Figure 1.6). A further step in the activation and signalling of 
Eph receptors is the transphosphorylation of two tyrosine residues in the 
juxtamembrane region, as determined by structural studies on EphB2 (Wybenga- 
Groot et al., 2001). This phosphorylation results in a conformational change that allows 
the tyrosine kinase domain to be activated. The kinase activity is then stimulated by the 
phosphorylation of the activation loop within the kinase domain, which subsequently 
exposes newly autophosphorylated tyrosines for interaction with SH2/SH3 domains of 
target scaffolding/adaptor proteins. The phosphorylated tyrosine residue in both the 
juxtamembrane and kinase domain, serves as docking sites for a series of signalling 
proteins such as Ras-GTPase activating protein (RasGAP), Src and Abl family of non­
receptor tyrosine kinases, low molecular weight phosphotyrosine phosphatase (LMW- 
PTP), phospholipase Cy, phosphatidylinositol 3-kinase, and adaptor proteins SLAP, 
Grb2, GrblO, and Nek ((Bruckner and Klein, 1998; Flanagan and Vanderhaeghen, 
1998; Kalo and Pasquale, 1999); Figure 1.7). The C-terminal PDZ-binding domain of 
some Eph receptors are involved in interaction with PDZ-domain-containing molecules 
such as such as AF6, Pickl, Syntenin, and Gripl and Grip2 (Cheng et al., 2002). Many 
of these proteins are believed to function as scaffolds for the assembly of multiple 
signalling protein complexes at the membrane.
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1.7.3 Structure and signalling through A-class ephrins
Both A- and B-class ephrins share a unique conserved extracellular receptor-binding 
domain. But unlike the B-class, ephrinA ligands do not have a cytoplasmic domain and 
are tethered to the cell membrane by the hydrophobic GPI anchor. Nevertheless, there is 
evidence suggesting that ephrinAs have intrinsic signalling capabilities. Genetic studies 
in C. elegans in which the GPI-anchored ephrin homologues were mutated, suggest that 
they are capable of reverse signal transduction in response to engagement with the 
single Eph receptor VAB-1 (Chin-Sang et al., 1999; Wang et al., 1999). Furthermore, 
studies in cell culture have shown that the GPI-anchor protein CD59 can transmit an 
intracellular signal (Murray and Robbins, 1998) and that ephrinA5 is able to modulate 
cellular adhesion via Fyn in an integrin-dependent manner, when bound to its cognate 
Eph receptor (Davy et al., 1999; Davy and Robbins, 2000). The precise mechanisms 
governing ephrinA signalling remain to be uncovered.
1.7.4 Structure and signalling through B class ephrins
EphrinB ligands possess a single transmembrane domain and a short cytoplasmic 
region, consisting of five conserved tyrosine residues and a C-terminal PDZ-binding 
motif (Figure 1.5). The tyrosine residues can be phosphorylated and serve as docking 
sites for proteins containing SH2/SH3 domains (Figure 1.6), while the PDZ-binding 
motif attracts PDZ-domain containing molecules. All these structural motifs control the 
binding and subsequent activation of specific Eph receptors, often referred to as 
“forward” signalling. This simultaneously mediates membrane localisation and may 
subsequently lead to activation events through the B-class ligands itself that may 
eventually eliciting distinct biological responses, in a process termed “reverse” 
downstream signalling.
Much attention has been given to the study of signalling events occurring in B class 
ligands upon receptor engagement. It has been reported that the cytoplasmic tyrosine 
residues of ephrinBs become phosphorylated (Figure 1.6), which may lead to a 
conformational changes that in turn results in the recruitment of interacting cytoplasmic 
proteins and the activation of intracellular signalling cascades (Song, 2003). An
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assortment of adaptor proteins has been found to interact with the PDZ-domain of 
ephrinBs. These include syntenin, G ripl/2, Pickl, the phospho tyrosine phosphatase 
FAP-1, PHIP that is related to Par-3, and more recently, PDZ-RGS3 (Lin et al., 1999; 
Lu et al., 2001). Association with these PDZ-domain containing proteins may facilitate 
the localisation of ephrinB 1 into sphingo-lipid/cholesterol-enriched raft membranes, 
which could contribute to clustering and downstream signalling (Bruckner et al., 1999). 
Interestingly, it has been demonstrated that EphB receptor engagement of ephrinB 1 
causes rapid recruitment of src-family protein tyrosine kinase (SFKs) to raft 
membranes, leading to transient Src family kinase (SFK) activation (Palmer et al., 
2002). The PDZ domain containing protein tyrosine phosphatase PTP-BL is 
subsequently recruited to the ligands cytoplasmic domain and can mediate its 
dephosphorylation.
The first evidence of reverse signalling by ephrins comes from genetic studies of EphB2 
and its role in axon guidance in the central nervous system. Mice lacking EphB2 show 
defects in axon guidance in the formation of the anterior commisure while this develops 
normally in mutants expressing a catalytically inactive form of EphB2 (Henkemeyer et 
al., 1996). This suggests that the ephrinB ligands are able to actively guide axons in the 
absence of functional Eph receptor signalling. This is further supported by studies of 
retinal axon pathfinding in the optic disc. Axon guidance was found to be independent 
of the kinase domain of both EphB2 and EphB3, thus reliant on ephrinB2 reverse 
signalling (Birgbauer et al., 2000). In addition, it has been shown that the cytoplasmic 
domain of ephrinB2 acquires an intrinsic reverse signalling role that is essential for 
proper vascular morphogenesis (Adams et al., 2001). Several additional ephrinB2 
knock-in mice have been generated in which the cytoplasmic domain was either 
truncated, replaced or modified ((Cowan et al., 2004) and unpublished data). Although 
the outcome of these studies is controversial, the cytoplasmic domain of ephrinB2 may 
regulate blood vessel and/or heart development. The use of an animal cap assay 
generated from a combination of lineage tracer dye and RNA injections into zebrafish 
embryos, has demonstrated that bidirectional signalling between ephrinB-EphB leads to 
restricted cell intermingling between adjacent cell populations (Mellitzer et al., 1999). It 
was shown that unidirectional activation through either Ephs or ephrinB2 was sufficient 
to restrict cell-cell communications between different cell populations, with the 
decrease in gap junction formation, despite intermingling (Mellitzer et al., 1999).
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In vitro studies have uncovered that ephrinB 1 reverse signalling activates the JNK 
pathway leading to changes in cell morphology that is independent of tyrosine 
phosphorylation (Xu et al., 2003). It was shown that the adaptor protein Grb4 is 
recruited to tyrosine-phosphorylated ephrinB 1 via its SH2 domain, which resulted in the 
reorganisation of the actin cytoskeleton and led to a rounded cell morphology (Cowan 
and Henkemeyer, 2001). Furthermore, the association of ephrinB 1 with Dishevelled 
(Dsh) was found to be induced by stimulation with the clustered EphB2 ectodomain 
(Tanaka et al., 2003). This led to the activation of RhoA GTPase and Rho kinase, and 
subsequently, cell repulsion.
1.7.5 From attraction to repulsion
As mentioned above, binding and activation of ephrins and Ephs require direct cell-to- 
cell interaction. The biological outcome of such interactions depend on cell type and 
context, but a general motif feature is the guidance of cell movements and the extension 
of cellular processes, which alters cell shape. Signals often involve the repulsion of Eph 
and ephrin expressing cells either in a unilateral or a mutual manner. A well studied 
example is the formation of hindbrain rhombomeres where Ephs and ephrins help to 
create boundaries between the cells of adjacent structures (Xu et al., 1999). Eph-ephrin 
signalling is also required for the fasciculation of axon tracts, guidance of axonal 
growth cones, guided migration of neural crest cells, and for the formation of 
topological maps in the brain (Holland et al., 1998; Holder and Klein, 1999).
The confusion still remains over how the initial adhesive interaction between Eph and 
ephrin proteins is converted into a repulsive signal. One possible solution to this 
problem may be ligand cleavage by the metalloprotease Kuzbanian/ADAMIO in 
response to binding between EphA3 and ephrinA2 (Hattori et al., 2000). The shedding 
of the ligand led to the disengagement of the cells involved and permitted efficient axon 
retraction in an in vitro assay. However, the relevance of this process in vivo and for the 
B-class ephrins remains unknown.
At sites of cell-cell contacts, endocytosis may be an alternative mechanism for the 
termination of adhesion between EphB-ephrinB complexes, which then permits
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detachment and repulsion (Marston et al., 2003; Zimmer et al., 2003). These 
endocytosis events require full-length receptor or ligand and activation of the small 
GTPase Rac, which is in turn required for internalisation of the Eph/ephrin complex. 
This process leads to the retraction of lamellipodia and causes the cells to disengage.
1.7.6 Eph/ephrin function in embryonic blood vessel development
Recent studies including gene inactivation experiments in mice, cell culture systems, 
and angiogenic assays have demonstrated essential roles of ephrin ligands and their 
cognate receptors in the morphogenesis of the embryonic vasculature.
1.7.6.1 Expression pattern in the vasculature
Expression patterns for ephrins and Eph receptors are highly dynamic during 
embryogenesis so that the sites of expression and receptor-ligand interaction change 
rapidly during development (Holder and Klein, 1999). Several members of Eph/ephrin 
molecules are expressed in the developing cardiovascular system.
The A-class ligand, ephrinA 1 has been detected by in situ hybridisation at multiple sites 
of vascular development in the mouse embryo. These include the endocardial cells 
lining the heart, the dorsal aorta, the primary head veins, intersomitic vessels and the 
limb bud vasculature (McBride and Ruiz, 1998). EphrinA 1 is a chemoattractant for 
endothelial cells and has angiogenic activity in vitro as well as in cornea pocket assays 
in vivo (Pandey et al., 1995; Daniel et al., 1996). EphA2, which is also expressed in the 
vasculature, is an important interactor of ephrinA 1. A dominant negative form of 
EphA2 has been shown to inhibit capillary tube-like formation in human venous 
endothelial cells (Ogawa et al., 2000). Furthermore, EphA2 has been found to be co­
expressed with ephrinA 1 in various implanted tumours lines in mice as well as in the 
cells of surgically removed human tumours, thus implicating possible involvement in 
tumour neovascularisation (Ogawa et al., 2000). However, neither the ephrinA 1 nor the 
EphA2 null mice exhibit any vascular phenotype ((Chen et al., 1996) and unpublished 
data).
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Important insights into the expression of B-class Eph RTKs and ephrins came from the 
insertion of |3-galactosidase (P-gal) reporter cassettes into the mouse ephrinB2 and 
EphB4 genes (Wang et al., 1998). As this leads to |3-gal expression under the control of 
the endogenous promoter and enhancer elements, the expression of ephrinB2 in arterial 
endothelial cells and of its cognate receptor, EphB4 in venous endothelial cells, was 
revealed. However, later studies reported low levels of ephrinB2 expression in venous 
endothelial cells as well as weak and patchy expression of EphB4 in the arteries (Shin et 
al., 2001). Nevertheless, ephrinB2 and EphB4 remain good markers for arterial and 
venous endothelial cells from the earliest stages of development in many species and 
are therefore widely used to define arterial-venous identity. It has also been shown that 
ephrinB2 expression expands to pericytes and vSMCs in the second half of embryonic 
development that persists into adulthood (Gale et al., 2001; Shin et al., 2001).
Other Eph/ephrin molecules are also expressed in the vascular system. EphrinB 1 
transcripts have been found in the endothelium but are not restricted to arterial or 
venous domains (Adams et al., 1999). In the endothelium of the developing kidney, 
ephrinB 1 is co-expressed with EphBl (Daniel et al., 1996). Clustered ephrinB 1 fusion 
protein promotes capillary-like assembly and cell attachment in endothelial cells (Stein 
et al., 1998). Both ephrinB 1 and ephrinB2 induce capillary sprout formation in cultured 
microvascular endothelial cells in vitro, similar to responses triggered by VEGF or 
Angiopoietins (Adams et al., 1999). EphB3 predominantly localises on veins but is also 
seen in some arteries in the yolk sac and in aortic arches (Adams et al., 1999). EphB2 
and ephrinB2 are expressed by mesenchymal cells surrounding certain blood vessels, 
suggesting a putative role in vessel wall development through mesenchymal-endothelial 
interactions (Adams et al., 1999).
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1.7.6.2 Insight into B-class Eph/ephrin function during blood vessel 
development from gene targeting studies
Many members of B-class Eph/ephrin molecules are expressed in the developing 
cardiovascular system, including ephrinB 1, ephrinB2, EphB2, EphB3 and EphB4. For 
some of these genes, their involvement in vascular morphologies has been firmly 
established through targeted inactivation studies in mice.
The knockout of ephrinB2 resulted in severe cardiovascular defects, growth retardation, 
and embryonic lethality at E10.5 with 100% penetrance (Wang et al., 1998; Adams et 
al., 1999). Mutant hearts were inflated, incompletely looped and displayed reduced 
myocardial trabeculation. Vascular morphogenesis was arrested at the primary capillary 
plexus stage and angiogenic remodelling, such as branching and sprouting of vessels in 
the head and yolk sac, was impaired. Moreover, the dorsal aorta, with a low penetrance, 
and the anterior cardinal vein, with complete penetrance, were disrupted suggesting that 
ephrinB2 is required for some aspects of vasculogenesis. Overall, the vascular defects 
were observed in both arterial and venous domains of the vascular network. However, 
as ephrinB2 is only expressed on arterial endothelium, this may not be cell autonomous. 
The generation of knock-in mice (ephrinB2AC/AC) expressing truncated ephrinB2 without 
the cytoplasmic domain, corroborates with this view (Adams et al., 2001). These mice 
displayed defects in angiogenic remodelling that where reminiscent of those observed in 
ephrinB2 knockout mice, confirming that the ligand reverse signalling through the 
cytoplasmic tail is critical during embryonic vascular development. However, 
replacement of the cytoplasmic domain by (3-gal permitted vascular morphogenesis and 
full embryonic development (Cowan et al., 2004).
The ablation of EphB4 expression in mice, also resulted in mid gestation lethality and 
mimicked the phenotype of the ephrinB2 knockout (Gerety et al., 1999). This signified 
the essential role of reciprocal ephrinB2/EphB4 interactions and the mediated 
bidirectional signalling for fundamental steps during vascular morphogenesis.
Targeted disruption of either EphB2 or EphB3 showed no overt defects in blood vessel 
development. However, 30% of mice lacking both receptors displayed similar vascular
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defects (Adams et al., 1999). The partial penetrance phenotype suggests that other EphB 
receptors may compensate for EphB2 and EphB3 function in the vasculature.
1.7.6.3 EphrinB2-mediated interactions between endothelial cells and 
perivascular cells
In recent years, there has been a steady increase in evidence for the involvement of 
ephrinB2 in the communication between the endothelium and perivascular cells of 
mesenchymal origin. In ephrinB2 knockout embryos, mesenchymal or pericyte cells 
surrounding the blood vessel are abnormally rounded compared to the normally 
elongated morphology (Wang et al., 1998). A ngl expression, normally produced by 
cells supporting the endothelium was reduced in ephrinB2 knockout mice, as well as the 
expression of the cognate receptor Tie2 in endothelial cells (Adams et al., 1999). As 
Tie2 expression was also reduced in ephrinAC/AC mice, ephrinB2 reverse signalling may 
be required for endothelial-mesenchymal cell interactions. However, it is still unclear 
whether ephrinB2 directly regulates Tie2. As embryonic development proceeds, 
ephrinB2 expression in the arterial endothelial cells progressively extends to the 
surrounding vascular smooth muscle cells and pericytes (Gale et al., 2001; Shin et al., 
2001). The involvement of ephrinB2 in promoting EC-mural cell proliferation and 
interaction has been highlighted by in vitro experiments involving OP9 stromal cells 
that over-express ephrinB2 (Zhang et al., 2001). This promoted growth and sprouting of 
ephrinB2- expressing endothelial cells as well as the recruitment and proliferation of 
smooth muscle cells. In addition, it has been reported that the activation of EphB2 and 
its ligands can promote smooth muscle cell proliferation in cultured bovine vascular 
smooth muscle cells (Woods et al., 2002).
In summary, data available to date indicates that the activation of Eph-ephrins 
signalling can induce vSMC proliferation in vitro but the actual roles in vivo require 
further investigation.
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1.7.6.4 Roles of ephrinB2 in tumorigenesis?
Ephrin ligands and Eph receptors are frequently over-expressed in a wide variety of 
cancers affecting breast, lung and the gastrointestinal system as well as in melanomas 
and neuroblastomas. Several reports have also indicated their roles in tumour 
angiogenesis (for comprehensive reviews, see (Dodelet and Pasquale, 2000; Nakamoto 
and Bergemann, 2002)). Mice harbouring a LacZ cassette in the ephrinB2 gene 
demonstrated expression of ephrinB2 in blood vessels at sites of neovascularisation and 
in tumours formed by Lewis lung carcinoma and B16 melanoma cells (Gale et al., 2001; 
Shin et al., 2001). It is therefore conceivable that ephrinB2 may have an intrinsic role 
in the formation of the tumour vasculature and may be a potential therapeutic target 
along with EphB4. It has been shown that melanoma cells expressing soluble EphB4 
(sEphB4) proliferate normally as a monolayer, but at a reduced rate when grown as 
three-dimenstional cultures in vitro (spheroids) or in subcutaneous tumours in vivo 
(M artiny-Baron et al., 2004). Analysis of the tumour revealed a reduction in 
microvessel density.
1.8 PDGF/PDGFR Gene Family
Platelet-derived growth factor (PDGF) was originally purified from platelets isolated 
from blood serum plasma. Since then, it has been characterised as a potent mitogen for 
many cell types, particularly those of mesenchymal or neuro-ectodermal origin, 
including fibroblasts, smooth muscles, epithelial and glia cells (Heldin and Westermark, 
1999; Betsholtz et al., 2001). In cell culture assays, PDGF is involved in many aspects 
of cellular signalling events controlling proliferation, migration, differentiation survival 
as well as the deposition of extracellular matrix (ECM) and the release of tissue 
remodelling factors (Hoch and Soriano, 2003). The generation of knockout mice has 
revealed that many of the cellular responses to PDGF are crucial for mouse embryonic 
and postnatal development of several tissues and organs. PDGF has been also 
associated with pathological diseases such as atherosclerosis, fibrotic diseases, tumour 
malignancies, diabetic retinopathy and glomerulosclerosis (Heldin and Westermark, 
1999) (Lindblom et al., 2003).
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1.8.1 The PDGF signalling pathway
The PDGF family is comprised of four ligands, PDGF-A, -B, and the recently 
discovered PDGF-C and -D . The ligands exist as secreted disulphide-bonded 
homodimers, but only PDGF-A and -B  are able to form heterodimers. PDGFs are 
recognised by two tyrosine kinase receptors, PDGFRa and PDGFRp, which can form 
homodimers and heterodimers with different affinities with the ligands (Figure 1.8).
Mature PDGF-A and -B  chains consist of around 100 amino acid residues and display 
60% homology. From a structural aspect, PDGF belongs to the PDGF/VEGF super­
family of growth factors as it consists of eight cysteine residues that are also evident in 
the VEGF isoforms and placenta growth factor (Heldin and Westermark, 1999). Two of 
these residues are used to form interchain disulphide bridges that stabilise the dimer, 
while the remaining six residues are involved in forming interchain disulphide bonds.
Mature PDGFa and p receptors have the molecular size of ~170 kDa and ~180 kDa 
respectively. Structurally, they consist of an extracellular ligand-binding domain with 
five immunoglobulin-like domains, a transmembrane domain, and an intracellular 
region that harbours a juxtamembrane domain and a split tyrosine kinase domain 
(Ronnstrand and Heldin, 2001). Upon PDGFR engagement with the ligand, this leads to 
a sequence of events beginning with the dimerisation of the receptor. This allows 
subsequent transphosphorylation of the tyrosine residues between the two receptors that 
results in the activation of the kinase domain. This leads to the autophosphorylation of 
several key tyrosine kinase residues that are important for further phosphorylation of 
subsequent downstream substrates (Ronnstrand and Heldin, 2001). Tyr849 and Tyr857 
are the key tyrosine residues located in the tyrosine kinase domain of PDGFRa and 
PDGFRp respectively, which regulate the kinase activity. In addition, the 
phosphorylation of Tyr579 and Tyr581 found in the juxtamembrane of PDGFRp was 
found to be required for complete kinase activation and the association of the effector 
molecule Src (Baxter et al., 1998). The phosphorylation of these tyrosine residues leads 
to the recruitment of different signalling molecules containing Src homology 2 (SH2) 
domains, which are capable of binding to the other phosphorylated tyrosine residues. 
Molecules containing SH2 domains that bind to PDGFRs include the Src family kinases
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(SFKs), the regulatory p85 subunit of phosphoinositol 3'-kinase (PI3-kinase), the 
GTPase-activating protein RasGAP, the adaptor molecule Grb2 and She, and the 
tyrosine phosphotase SHP-2. These molecules bind to specific residues and mediate 
diverse roles in signalling events that affect cell mitogenesis, chemotaxis and survival 
(Heldin and Westermark, 1999; Pawson et al., 2001). As 13 tyrosine residues have been 
identified in PDGFRp so far, of which many binding partners have been identified, each 
one could regulate the initiation of the different intracellular signalling pathways 
(Ronnstrand and Heldin, 2001). Following PDGFR activation, the receptor is 
subsequently internalised and rapidly degraded.
Besides the investigation of signalling transduction pathways downstream of PDGFRs 
in tissue culture, there is some evidence suggestive of crosstalk between other receptor 
pathways and PDGFRs. For example, Bruckner and co-workers reported that PDGF 
could induce ephrinB 1 phosphorylation (Bruckner et al., 1999).
1.8.2 In vivo studies
The involvement and importance of PDGF-A, -B and PDGFRa and p in developmental 
processes, has been elucidated by the generation of knockout mice (Leveen et al., 1994; 
Soriano, 1994; Bostrom et al., 1996; Soriano, 1997). The PDGF-B, PDGFRa and p 
knockouts are lethal at prenatal stages while PDGF-A mutants die during early postnatal 
life. These studies uncovered the role of PDGFs in the control of proliferation, 
migration and survival of certain populations of glial progenitor cells and mesenchymal 
cells. These cells are subsequently involved in development of the cardiovascular 
system, the epithelial organs, the central nervous system and the skeleton (Betsholtz, 
2004). An extensive series of point mutations have also been generated in the mouse to 
investigate the requirement of specific signal transduction pathways downstream of the 
PDGFRp (Tallquist and Kazlauskas, 2004). Remarkably, mutant mice with the loss of 
six effector binding sites (F7) do not phenocopy null mutants and are viable. This 
suggests that PDGFRp must retain some signalling capacity even though known signal 
transducers are unable to directly bind to the receptor. However F7 mice displayed a 
reduction in vSMCs in various tissues including the eye, heart and kidney.
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1.8.3 Involvement of PDGF-B and PDGFRp in blood vessel 
development
PDGF-B and PDGFRp knockouts die at late gestation from extensive microvascular 
haemorrhaging and show defective formation of kidney glomeruli and oedema. These 
defects suggest that PDGF-B/PDGFRp signalling promotes the proliferation of 
vSM C/pericyte progenitors and their recruitment to new blood vessels during 
embryogenesis (Figure 1.9).
Sprouting ECs express high levels of PDGF-B at their tips. This then acts as a short- 
range paracrine factor to attract surrounding PDGFRp expressing pericytes and 
subsequently vSMCs, which then cover the nascent blood vessels. The perturbation of 
the PDGF-B/PDGFRp signalling interactions by gene inactivation in mice, led to severe 
shortage of mural cell coverage of blood vessels, dilation of microvessel, 
microaneurysms and widespread bleeding. The endothelium is the critical source of 
PDGF-B for vSM C/pericyte recruitment, as demonstrated by the generation of 
endothelial-specific PDGF knockout mice (Enge et al., 2002). Furthermore, the loss of 
a single allele of either PDGF-B or PDGFRp reduced the pericyte number and 
suggested that gene dosage is important.
An additional control mechanism that may further regulate the short-range interaction 
of PDGF-B is the binding of PDGF-BB molecules to the surrounding extracellular 
matrix, through a heparan sulphate proteoglycans (HSPG) binding sequence, termed 
the “retention m o tif’. Mice lacking this motif exhibit reduced pericyte density and 
impaired pericyte investment to the microvessel wall (Lindblom et al., 2003). The 
reported loose attachment of the pericytes to the abluminal surface of the endothelium 
and protruded cellular processes of these cells away from the vessels suggested that 
PDGF-B retention and restricted diffusion (which may create a concentration gradient), 
is critical for proper association of pericytes to the micro vessel wall.
Mesangial cells are a specialised form of mural cell that are restricted to the kidney. 
They normally constitute ~30% of the glomerular cells and appear to promote 
intussusception of invading vascular loops into the capillary network in the glomeruli.
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The presence of mesangial cells is essential for the generation of large-surface areas 
needed for efficient blood filtration (Betsholtz, 2004). The defective formation of the 
glomeruli in PDGF-B and PDGFRp mutants has been attributed to the almost complete 
lack of mesangial cells. Furthermore, both PDGF-B retention mutants and endothelial- 
specific knockouts exhibit inflated glomerular capillary loops due to delayed mesangial 
cell recruitment. However, this defect was corrected one month after birth and the 
required physiological level of mesangial cells had been recruited. It is possible that 
other molecules, such as PDGF-D, could be involved and are able to compensate for the 
loss of PDGF-B in mutants. Nevertheless, PDGF-B retention mutants develop 
glomerulosclerosis and proteinuria as adults.
1.9 Conclusion and the aim of the thesis
In conclusion, the studies described here have shown that ephrinB2 and its receptor, 
EphB4, are involved in early angiogenic remodelling of the embryo, but whether 
endothelial ephrinB2 expression is essential for blood vessel development remains to be 
determined. The work described above has also established that PDGFRp signalling is 
an important regulator of mural cell proliferation and recruitment. Expression studies 
indicate that Eph/ephrin molecules may be also involved in these processes, especially 
ephrinB2. The aim of the thesis was to characterise of the role of ephrinB2 in 
endothelial and mural cell populations.
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Angiogenic factors
Acidic and basic fibroblast growth factor (aFGF, bFGF)
Vascular endothelial growth factor family and their receptors (VEGF, VEGFR) 
Platelet derived growth factor BB and receptors (PDGF-BB, PDGFR) 
Angiopoeitins and their receptor (Ang1, Ang2 and tie2)
Hepatocyte growth factor (HGF)
Ephrins and their Eph receptors 
Pleiotropin
Insulin-like growth factor (IGF-1)
Transforming growth factor-p1 (TGF-p1)
Tumour necrosis factor-a (TNF-a)
Interleukins (IL-1, IL-4, IL-6 , IL-8 )
Histamine
Bradykinin
Prostagladins (PGD-E1, PGD-E2)
Heparin
Adhesion molecules (integrins: a$3, 0 ^ 5 , a ^ ,  VE-cadherin) 
Metalloproteases (collagenase, stromelysin, MMP-2)
Angiogenin
Anti-angiogenic factors
Interferons (IFN-a, IFN-p)
Thrombospondins (TSP-1, TSP-2)
Tissue inhibitor of metalloproteases (TIMP-1, TIMP-2, TIMP-3) 
Endostatin (collagen XVIII fragment)
Angiostatin
Prolactin
Platelet factor 4 (PF-4)
Interleukins (IL-12.IL-18)
Heparinase
Prolactin
Vasostatin, calreticulin
Table 1.1: Angiogenic and anti-angiogenic factors
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Molecules Embryonic stage 
of lethality
Vascular Phenotype
H IF1a''or
H IF ip "
10.5 Defective yolk sac vasculogenesis with 
intact endothelial cell differentiation
VEGF-A’" 10.5 No dorsal aorta, defective 
haematopoiesis
VEGFR1"-(flt1) 8.5-9.5 Endothelial cell differentiation intact. 
Vascular disorganisation and angioblast 
overpopulation
VEGFR2"(flk1) E8.5-9.5 Endothelial and haemangioblast 
migration and differentiation failure
VEGFR3" 9.5 Vasculogenesis and angiogenesis intact, 
large vessels
disorganised with lumen defects
Angr'- E10.5 Defective organisation , remodelling
Ang2" E12.5-P Defect in vessel integrity, haemorrhaging
T ie r" E13.5— 14.5 Defective vascular integrity/endothelial 
survival in angiogenesis, oedema and 
haemorrhaging
Tie2‘" E10.5 Defective organisation and remodelling, 
sprouting and heart trabeculation
ephrinB2" E10.5 Defective organisation and remodeling, 
sprouting, heart trabeculation, and extra- 
embryonic vessel fussion
EphB2"7EphB3',‘ E10.5 (only 30% 
penetrance)
Defects in sprouting, remodelling and 
organisation
EphB4‘" E10.5 Defective organization and remodeling, 
sprouting, heart trabeculation, and extra- 
embryonic vessel fussion
PDGF BB" E16-19 Dilated heart and aorta, microvessel 
leakage and microaneurysm
PDGFRP" E16-19 Dilated heart and aorta, microvessel 
leakage and microaneurysm
VE-cadherin'" E10.5 Defective anterior large vessels and 
failure to establish yolk sac vascular 
plexus
TG Fpr" E10.5 Failure of endothelial differential, 
haematopoiesis and vessel formation
Table 1.2: Molecules required for proper embryonic vascular development
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ang io b la s t
Vasculogenesis
Angiogenesis 
sprouting
i n t u s s u s c e p t i v e
growth
branching
regression
pruning
Vascular myogenesis
SMC
recruitment
capillary
vein
mature network
Figure 1.1: Formation of new blood vessels
(Carmeliet P. and Collen D., (2000) Journal of Pathology 190:387-405) 
Angioblasts differentiate into endothelial cells which assemble into a primitive 
vascular network (vasculogenesis). This first network matures via different 
modes of vascular growth (angiogenesis) and recruits smooth muscle cells 
(SMC) to cover the endothelial tubules. This process results in a mature 
vascular network comprising of established arteries, capillaries and veins.
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Figure 1.2: Multiple steps and factors involved in angiogenesis
(Distler J. W. et al. (2003) Q J Nucl. Med 47(3):140-161)
First steps of angiogenesis involve vasodilation and increased vascular 
permeability with exudation of high molecular weight plasma proteins such as 
fibrinogen. After detachment of vascular smooth muscle cells (SMC), the vessel 
wall is destabilised and perivascular extracellular matrix (ECM) is degraded. This 
enables endothelial cells (EC) to proliferate and migrate along gradients of 
chemotactic agents in the hypovascularised areas. Once the target region has 
been reached, the ECs assemble and form tube-like structures. Finally, 
mesenchymal cells (MC) proliferate and differentiate into pericytes (PC) or 
vSMCs or that form the outer layers of the vessel wall.
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PC S M C
E C
oE C
E C  p ro life ra tio n EC  d iffe ren tia tio n
m ig ra tio n  q u iescence
survival
Figure 1.3: Mural cell interactions with endothelial cells
(Carmeliet P. and Collen D., (2000) Journal of Pathology 190:387-405) 
Mural cells, comprising of smooth muscle cells and pericytes, significantly 
determine vascular development. They inhibit proliferation and migration, 
and induce differentiation, quiescence and survival of endothelial cells.
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Tunica
Endothelium
Tunica media
(smooth muscle cells; elastic, reticular, 
collagenous fibers; external 
elastic lamina)
Subendothelial
layer
Internal elastic 
lamina
Subendothelial layer Tunica intima
Tunica adventitia
(collagenous and elastic tissue and 
vasa vasorum)
Large Vein
Tunica intima
Endothelium
Muscular Artery
adventitia
(collagenous 
connective tissue, 
fibroblasts, 
elastic fibers, 
smooth muscle 
cells, and 
vasa vasorum)
Internal elastic lamina
Tunica media
(smooth muscle 
and fibroelastic 
connective 
tissue)
Valve
Figure 1.4: Structural differences between a muscular artery and a large vein
with their multiple layers
(Gartner L. and Haitt. J., (2000) Color Atlas of Histology Page: 154)
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PDZ-binding motif
Cytoplasmic tailGpi anchor
ephrinBephrinA
Cysteine rich region Globular domain
Fibronectin-type III repeats
Plasma 
membrane Transmembrane region 
® u  Juxtamembrane region
Kinase domain
SAM domain
PDZ-binding motif 
Eph receptor
Figure 1.5: General features of Eph receptors and ephrins
(Kullander K. and Klein R., (2002) Nat. Rev. Mol. Cell. Biol. 7:475-486) 
A schematic diagram showing an ephrin-expressing cell (top) 
interacting with an Eph-expressing cell (bottom). Structural domains 
and tyrosine phosphorylation sites (P) are indicated.
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Intracellular
Extracellular
Intracellular
PDZ
C ytoplasm ic tail
R eceptor-binding dom ain
Ligand-binding dom ain
C ysteine-rich dom ain 
Fibronectin III
Fibronectin
O'
I  I
?p
.
K inase
Figure 1.6: Activation of bidirectional Eph-ephrinB signalling
pathway
(Himanen J. and Nikolov D., (2003) Trends Neurosci. 26(1):46-51 
Diagram showing that Eph and ephrin molecules form a 2:2 
circular heterotetramer, which leads to tyrosine phosphorylation in 
their cytoplasmic domains. The receptor binding domain of the B- 
class ephrins is shown in red, the ligand binding domain of Ephs in 
blue, and kinase domain and sterile-a-motif (SAM) in green. All the 
other structural elements are indicated in grey and the phosphate 
groups are purple.
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RasGAP Adhesion
ERK/MAPK
Ephexm
Plasma membrane
Proliferation
Cytoskeleton dynamics 
neurite extension
::i :i3s
Integrin
Figure 1.7: Adaptor interactions with Eph receptors
(Kullander K. and Klein R., (2002) Nat. Rev. Mol. Cell. Biol. 7:475-486) 
Diagram showing the adaptor molecules that interact with Eph 
receptors. Selected molecular cascades and biological effects are 
indicated.
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Ligands
CC
AA AB BB DD
Receptors
Extracellular
Intracellular
PD G FR aa
homodimer
PDGFRap
heterodimer
PDGFRpp
homodimer
Figure 1.8: PDGF ligands and PDGFR receptors
(Hoch R. and Philippe S., (2003) Development 130(20):4769-4784) 
A schematic diagram showing the homo- and heterodimeric 
complexes of the four known PDGF family ligands and their 
interactions with the cognate receptors PDGFRaa, a p  and pp.
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Nascent endothelial sprout 
expressing PDGFB
g y VSMC or pericyte 
expressing PDGFRp
Vascular endothelium  
a  f l b
Primitive vascular 
plexus or artery
Figure 1.9: Vascular mural proliferation, survival and migration
(Hoch R. and Philippe S., (2003) Development 130(20):4769-4784)
During angiogenic remodelling, PDGFB is expressed in nascent vascular 
endothelial sprouts (a) leading to the proliferation of PDGFRp-expressing 
pericytes and vascular smooth muscle cells (VSMC) near arterial walls and 
primitive vascular plexa (b). PDGF also directs the migration of mural cells 
along the endothelial sprouts (b,c). Upon reaching their destination, vSMC and 
pericytes associate tightly with the endothelium (c) and form the outer walls of 
the vessel wall. Survival and anti-proliferative factors produced by the mural 
cells stabilise nascent vessels.
49
Chapter2
Chapter2 I Materials and methods
Materials
2.1 Chemicals and reagents
With the exception of those listed below, all chemicals/reagents were purchased from 
Sigma-Aldrich or BDH/Merck. Reagents were of analytical grade or the highest grade 
available.
Chemicals &_Reaaents Corrmanv
Agarose Invitogen Life Technologies
dNTPs Promega
Mowiol* Calbiochem
TRIzol™ Reagent Gibco BRL
Trypsin/EDTA Invitogen Life Technologies
Vectashield* Vector Laboratories Inc
Shandon Cryomatrix™ Thermo Electron Co.
X-Gal Novabiochem
2.2 Buffers and solutions
All buffers and solutions were made as described below. “RT” indicates room 
temperate, “Filter” indicates sterilisation using a 0.2/^m filter.
Buffer & Solutions Contents
L-agar 1% bacto-tryptone, 0.5% yeast extract, 170mM NaCI, 
15% agar
L-broth 1% bacto-tryptone, 0.5% yeast extract, 170mM NaCI
PBS 140mM NaCI, 2.5mM KCL, 10mM Na2H P04 (pH7.2), 
1.5mM KH2P 04
PBS-T PBSA + 0.1% Tween-20
PCR Buffer 10x (pH 8.3) 100mM Tris-HCL, 15mM MgCI2*6H20, 500mM KCL
SSC 20x 3M NaCI, 0.3 Sodium Citrate
Tail Buffer 50mM Tris-HCL (pH8.0), 100mM NaCI, 100mM 
EDTA, 1% SDS
TBE Running Buffer (1x) 89mM Tris base, 89mM boric acid, 2mM EDTA
TE 10mM Tris-HCL (pH 8.0), 1mM EDTA (pH 8.0)
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2.3 Enzymes
All enzymes were obtained from New England Biolabs with the following exceptions.
Enzvme ComDanv
AMV Reverse Transcriptase Roche
Calf intestinal alkaline phosphatase (CIP) Roche
DNase I (RNase free) Roche
DNA Polymerase I (Klenow) Amersham Biosciencecs
Pfu Turbo® DNA Polymerase Stratagene
Proteinase K Gibco BRL
RNA polymerases (T3, T7, Sp6) Roche
RNase A Sigma
2.4 Immunoreagents
All antibodies were used at the concentrations indicated below. They were all used for 
immunoflourescence unless stated otherwise.
Primary Antibody Isotype Dilution Company
a-Smooth Muscle Actin (SMA) 
Unconjagated (Clone 1A4)
Mouse (IgG) 1:300 Sigma Aldrich
a-SMA-Cy3(Clone 1A4) Mouse (IgG) 1 300 Sigma Aldrich
p-Galactosidase (ab616) Rabbit (IgG) 1 1,000 Abeam
Anti-digoxigenin AP-conjugate Sheep (Fab fragments) 1 2,000 Roche
Desmin (Clone D33) Mouse (IgG) 1 200 Dako
EphB2 (Catalogue No. AF467) Goat (IgG) 1 200 R&D Systems
EphB3 (Catalogue No. AF432) Goat (IgG) 1 200 R&D Systems
EphB4 (Catalogue No. AF446) Goat (IgG) 1 200 R&D Systems
Ephrin-B2 (Catalogue No. AF496) Goat (IgG) 1 200 R&D Systems
LYVE-1 Rabbit (IgG) 1 1,000 Kari Alitalo (gift)
PECAM-1 (CD31 -Clone:MEC13.3) Rat (IgG) 1 300 PharMingen
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Secondary Antibody Isotype Dilution Company
Alexa Fluor'*' 488 Anti-Goat IgG Donkey 1:500 Molecular Probes
Alexa Fluor® 488 Anti-Mouse IgG Goat 1:500 Molecular Probes
Alexa Fluor® 488 Anti-Rabbit IgG Goat 1:500 Molecular Probes
Alexa Fluor® 350 Anti-Rabbit IgG Goat 1:500 Molecular Probes
Cy™3-conjugated Anti-Rat IgG Goat 1:500 Jackson
2.5 Miscellaneous
The following table lists the remaining products that were used.
Product Comoanv
Molecular Biology
Oligonucleotides Sigma Genosys
QIAGEN® Plasmid Maxi Kit Qiagen
QIAprep® Spin Miniprep Kit Qiagen
QIAquick® Gel Extraction Kit Qiagen
QIAquick® PCR Purification Kit Qiagen
Cell Culture
DMEM Invitrogen Life Technologies
E4 Medium 10x Cancer Research UK
Foetal Calf Serum Invitrogen Life Technologies
Interferon y Gibco BRL
L-Glutamine 200 mM (100x) Invitrogen Life Technologies
LipofectAMINE™ Invitrogen Life Technologies
PBS Cancer Research UK
Penicillin-Streptomycin (100x) Invitrogen Life Technologies
Tissue Culture Plastic-ware Corning, Falcon and NUNC
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2.6 List of suppliers and distributors
Company Location
Abeam Limited Cambridge, UK
Applied Biosystems Foster City, California, USA
BD Biosciences Oxford, UK
Boehringer Mannheim Gmbh Mannheim, Germany
Cambridge Bioscience Cambridge, UK
Corning Schiphol-Rijk, Holland
DakoCytomation Cambridgeshire, UK
Dynal Biotech UK Wirral, UK
Invitrogen Life Technologies Paisley, UK
Promega Southampton, UK
Qiagen West Sussex, UK
Novabiochem Nottingham, UK
New England Biolabs Hitchin, UK
Peprotech EC Ltd. London, UK
Perkin-Elmer Co. Foster City, California, USA
R&D Systems Inc. Minneapolis, USA
Sigma-Aldrich Company Dorset, UK
Stratech Scientific Limited Cambridgeshire, UK
Stratagene Amsterdam, Holland
Thermo Electron Co. Pittsburgh, USA
Vector Laboratories Inc Burlingame, California, USA
VWR International Ltd Dorset, UK
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Methods
2.7 Preparation, manipulation and analysis of plasmid DNA
2.7.1 Enzymatic manipulation of DNA fragments
Restriction enzymes and T4 DNA ligase were purchased from NEB and used for 
restriction digestions and DNA ligations, respectively. DNA polymerase Klenow 
fragment (NEB) and dNTPs (Gibco BRL) were used to blunt end DNA fragments. Calf 
intestinal alkaline phosphatase or shrimp alkaline phosphatase (Boehringer Mannheim) 
were used to remove 5’ phosphate groups from DNA fragments.
2.7.2 Bacterial transformation
XLl-Blue M RF’ Supercompetent Cells (Stratagene) were used for cloning of DNA. 
0.1 mg DNA from ligations or lng of plasmid DNA was added to a 50pl aliquot of 
competent cells on ice and left for 30 minutes. The transformation was performed 
according to the Manufacturer’s instructions. In brief, the bacteria were heat shocked at 
42°C for 45 seconds before being placed back on ice for 2 minutes. 500/d of L-broth 
was then added to the bacteria which were subsequently cultured for 45 minutes at 37°C 
with shaking at 150 RPM. 150-400/d of bacterial culture was spread out using glass 
beads on to L-agar plates containing 100//g/ml of ampicillin or 50//g/ml of kanamycin.
2.7.3 Preparation of plasmid DNA
To screen colonies after ligation and transformation, single colonies were picked and 
inoculated in 5 ml LB media containing the appropriate antibiotic, then grown overnight 
in a 37°C agitator. 2 ml of the overnight culture was used for small scale preparation of 
plasmid DNA whilst the remainder was stored at 4°C. The QIAprep® Spin Miniprep Kit 
was used for small-scale plasmid purification according to the manufactures 
instructions. DNA was eluted in TE or elution buffer (Qiagen) and stored at -20°C.
For large-scale maxi preparations, 0.5 ml of the overnight culture was added to 150 ml 
LB plus antibiotic and incubated overnight at 37°C in an agitator. Bacteria were pelleted 
by centrifugation at 6000 RPM for 15 min in a Beckman J2-21 centrifuge. The plasmid 
DNA was then purified using a QIAGEN® Maxi Kit according to manufacturers
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instructions. DNA was dissolved in TE or elution buffer (Qiagen) to a concentration of 
1 mg/ml and stored at -20°C.
2.7.4 Quantification of nucleic acids
DNA or RNA were diluted in 10 mM Tris-HCl pH 8.5 or water and placed in a quartz 
cuvette. Absorbance at 260nm and 280nm was read in a spectrometer with the correct 
respective DNA or RNA program set-up.
2.7.5 Purification of DNA from agarose gels
The percentage of agarose used in a gel was dependent on the size of DNA fragment 
that was to be purified: a 0.5kb fragment was typically run on a 2 % gel whilst 
fragments of 3kb and larger were run on 1 % or 0.8 % gels, lkb  and lOObp DNA 
ladders (NEB) were run alongside to determine fragment size. The gel slice containing 
the correct fragment was removed using a clean scalpel. DNA was then purified from 
the agarose using the QIAquick® Gel Extraction Kit according to the manufacturers 
instructions. DNA was resuspended in 10 mM Tris-HCl pH 8.5 or TE.
2.7.6 Polymerase Chain Reaction (PCR)
Amplification of DNA products for cloning were performed using Stratagene’s Pfu 
Turbo PCR kit. Reactions were carried out according to the manufacturers instructions.
2,1.1 Sequencing of DNA
All DNA sequencing were performed by the DNA Sequencing Service (Cancer 
Research UK) using the ABI® BigDye™Terminator Cycle Sequencing Ready Reaction 
Kit (Applied Biosystems) according to the manufacturers instructions. Briefly, 0.5pig 
template DNA was added to 3.2pmol sequencing primer and 8/d BigDye™Terminator 
mix in a total volume of 20/d. PCR were carried out as recommended by the 
manufacturer and DNA products were ethanol precipitated at room temperature for 15 
minutes by the addition of 300/d 95% ethanol, 5/d 3M sodium acetate (pH4.5) and 80/d 
dH20 . After centrifugation at 14,000 RPM for 20 minutes, the pellet was washed with
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500/d 70% ethanol, vortexed briefly, centrifuged as described above for 5 minutes, air 
dried, and then stored at -20°C until loading in the polyacrylamide sequencing gel.
2.8 Generation of transgenic lines using the PDGFRp genomic 
fragment
2.8.1 Generation of the PDGFRp-LacZ transgenic line
The PDGFRp genomic fragment was obtained as a gift from Dr. Christer Betsholtz. A 
reporter construct, containing the internal ribosomal entry site fused to the LacZ 
sequence (IRES-LacZ), was inserted into exon-4 of the 5.1 PDGFRp genomic fragment, 
via the EcoRV site (Figure 4.1). This PDGFRP-LacZ construct was linearised with the 
restriction enzyme Hpal and subsequently used for pronuclear injections into fertilised 
mice zygotes. A total of 12 transgenic founder lines were generated.
2.8.2 Generation of the PDGFRp-Cre transgenic line
A construct containing the internal ribosomal entry site fused to the Cre sequence 
(IRES-Cre), was inserted into exon-4 of the 5.1 PDGFRp genomic fragment as before 
(Figure 4.4). This PDGFRP-LacZ construct was linearised with the Hpal and 
subsequently used for pronuclear injections into fertilised mice zygotes. A total of 13 
transgenic founder lines were generated.
2.9 Analysis of genomic DNA
2.9.1 Isolation of genomic DNA from mouse tissue
Tail snips or yolk sacs were stored at -20°C until ready for processing. 500/d Tail 
Buffer (50mM Tris-HCL (pH8.0), lOOmM NaCI, lOOmM EDTA, 1% SDS and freshly 
added Proteinase K at 100/*g/ml) was added to the mouse sample. Digestion was carried 
out at 55°C overnight or for a minimum of 6 hours. 250/d of 6M NaCI was added and 
mixed for 5 minutes on an Eppendorf Mixer and the sample was centrifuged at 13,000 
RPM for 10 minutes after which the supernatant was decanted into a fresh 1.5ml 
microtube containing 500/d isopropanol and mixed as before. After 10 minutes of 
centrifugation at 13,000 RPM, the supernatant was decanted and the remaining pellet
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was washed with 70% ethanol and centrifuged as before. The pellet was then air dried 
and dissolved in 150jA of TE.
2.9.2 Genotyping Mouse Genomic DNA by PCR
Pic Taq polymerase (Cancer Research UK) was used for genotyping of mouse genomic 
DNA via PCR. A master mix was made up according to the number of samples and a 
typical cycling program is described in the table below.
Volume Temperature (°C) Time No. of
(Ml) (Minutes) Cycles
DNA Template 1.0 94 1 1
PCR Buffer 10x 2.5
dNTPs (2.5 mM of each) 2.5 94 1
Primer 1 (20pM) 1.25 Annealing Temp. 1 30-35
Primer 2 (20pM) 1.25 72 -J 1
Pic Taq Polymerase 0.5
Distilled Water 16 72 10 1
Total Volume 25 4 Forever
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Embryos and mice were routinely genotyped by PCR using the primers listed below. 
All primers were manufactured by Sigma-Genosys.
Mouse Line Primer Sequence 
5' to 3'
Anneal.
Temp.
Fragment
Size
ephrinB2
Conditional
Non-Recombinant
Forward B2Cs1 CTT CAG CAA TAT ACA 
CAG GAT G
62°C ~370 bp lox
-270  bp 
WT
Reverse B2Cas1 TGC TTG ATT GAA 
ACG AAG CCC GA
ephrinB2
Conditional
Recombinant
Forward B2Cs1 CTT CAG CAA TAT ACA 
CAG GAT G
62°C -370 bp KO 
(conditional)
Reverse B2Cas3 AAT ACT GTT ACT ACA 
GGG TCC
ephrinB2 KO Forward pFloxs3 CTG GGG ATG CGG 
TGG GCT CTA
62°C -1300 bp 
KO
Reverse Elf2as6 GGG CCG CAG TAA 
GTTTAAAAC
Tie1-Cre Forward Cre1 GCC TGC ATT ACC 
GGTCGA TGC AAC GA
70°C -720  bp
Reverse Cre2 GTG GCA GAT GGC 
GCG GCA ACA CCA TT
Tie2-LacZ Forward HHFW3 GCC TAT GAG AGG  
ATA CCC CTA TTG
62°C -720  bp
Reverse LZREV1 GGA ACA AAC GGC 
GGA TTG ACC G
Tie2CreER‘ Forward Cre1 GCC TGC ATT ACC 
GGT CGA TGC AAC GA
70°C -720  bp
Reverse Cre2 GTG GCA GAT GGC 
GCG GCA ACA CCATT
SMMHC-Cre Forward Cre1 GCC TGC ATT ACC 
GGT CGA TGC AAC GA
70°C -720  bp
Reverse Cre2 GTG GCA GAT GGC 
GCG GCA ACA CCATT
PDGFRp-LacZ Forward pR-LacZs ACA TGA CAT CAA 
CCA TAT CAG C
62°C -240  bp
Reverse pR-LacZas GTG AAA CCT CGC 
TGG TGG
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Mouse Line Primer Sequence 
5' to 3'
Anneal.
Temp.
Fragment
Size
PDGFRp-Cre Forward Cre1 GCC TGC ATT ACC 
GGT CGA TGC AAC GA
70°C -720 bp
Reverse Cre2 GTG GCA GAT GGC 
GCG GCA ACA CCATT
PDGFRp-KO Forward (3R1 ACA ATT CCG TGC 
CGA GTG ACA G
65°C -320 bp KO
-114 bp 
WT
Forward pR3 ATC AGC CTC GAC 
TGT GCC TTC TAG
Reverse pR2 AAA AGT ACC AGT 
GAA ACC TCG CTG
XlacZ4 (Pericyte- 
LacZ)
Forward PLacZ-E CAAT ACT ATG CAG 
ACT CTG GAA GTG
55°C -600 bp
Reverse PLacZ-3 CAA ACT CAT CAA TGT 
A TC TTA TC A TG TC
Immorto Forward Immos GCA TTG CCT GGA  
ACG CAG TGA GT
60°C -380 bp
Reverse Immoas GAA CAG ACT GTG 
AGG ACT GAG GG
Rosa26Reporter Forward Rosal AAA GTC GCT CTG  
AGT TGT TAT
55°C -370 bp 
transgenic
-600 bp 
WT
Reverse Rosa2 GCG AAG AGT TTG  
TCC TCAACC
Reverse Rosa3 GGA GCG GGA GAA 
ATG GAT ATG
2.10 Analysis of products following total RNA isolation
2.10.1 Isolation of total RNA from cells in culture
TRIzol® Reagent was used to isolate total RNA according to the manufacturers 
instructions. Total RNA pellets were air dried, resuspended in RNase-free water and 
stored at -80°C.
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2.10.2 Isolation of total RNA from mouse tissue
Freshly dissected tissue samples were homogenised using a pestle and mortar or 
immediately snap-frozen in liquid nitrogen for later use. Total RNA was isolated using 
the TRIzol® Reagent following the manufacturers instructions.
2.10.3 Synthesis of first strand cDNA
Using 1 pig of total RNA as a template, reverse transcription was carried out resulting in 
first strand cDNA synthesis, using the AMV Reverse Transcriptase (Roche) according 
to the manufacturers instruction. The resulting product, in a volume of 20/d, was stored 
at -20°C.
2.10.4 Synthesis of second strand cDNA by PCR and mRNA profile
Using the first strand cDNA as template, second strand synthesis and amplification was 
performed by PCR. By designing different specific primer pairs that lie in exons 
flanking the intronic regions, an expression profile was generated of endogenous 
mRNAs from the isolated cells in which the total RNA was extracted from. The typical 
cycling program for the PCR is shown in Section 2.7.2 and the primers used are listed 
below.
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Gene of 
Interest
Primer Sequence 
5' to 3’
Anneal.
Temp.
Fragment
Size
Desmin Forward Desmin-s CGA GCT GCT GGA CTT 
CTC CCT
64°C -220 bp
Reverse Desmin-as GCT GCA TCC ACA TCC 
GCT C
PDGFRp Forward PDGFRp-s AAT TCC GTG CCG AGT 
GAC AG
62°C -510 bp
Reverse PDGFRp-as ACG TAG CCA TTC TCG 
ATC ACA G
PECAM-1 Forward PECAM-1 s CAC CTC GAA AAG CAG 
GTC TC
64°C -680 bp
Reverse PECAM-1 as CAG CTT CAC TGC TTT 
GCT TG
EphB2 Forward Nuksl GCA CTT CGC TGG  
TGGCAG CTC
70°C -970 bp
Reverse Nukasl CTT GAT GCT GGT CTG 
GTA CTC
EphB3 Forward Sek4s1 GCT GGT GAG TTT GGG 
GAA GTG
68°C -990 bp
Reverse Sek4 as1 GTG ACC CCA ATC CTT 
AGC AG
EphB4 Forward Myk1s1 CAG GTG GTC AGC GCT 
CTG GAC
64°C -380 bp
Reverse Myk1as1 ATC TGC CAC GGT GGT 
GAG TCC
2.11 Histology, lacZ stainings, immunohistochemistry and in 
situ hybridisation
2.11.1 Fixation and paraffin-embedding of tissues for sectioning
Mouse tissues were dissected and fixed overnight in 4% paraformaldehyde (PFA- made 
in PBS at pH 7.4) at 4°C. They were then washed sequentially in the following 
solutions: 30 minutes in PBS at 4°C, 30 minutes in 0.9% NaCI in at 4°C, 2 x 1 5  minutes 
in 0.9% NaCI in 50% ethanol at RT, 2x 30 minutes in 70% ethanol in PBS at RT 
(tissues can be stored at this stage at 4°C), 60 minutes in 85% ethanol in PBS at RT, 60
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minutes in 95% ethanol in PBS at RT, 3 x 60 minutes in 100% ethanol at RT, 2 x 30 
minutes in Xylene at RT, overnight in Xylene at RT, 60 minutes in Paraffin/Xylene (1:1 
ratio) at 56 °C, 4x 60 minutes in Paraffin at 56°C. The samples were finally transferee! 
into embedding moulds filled with hot paraffin and allowed to solidify overnight at RT 
before cutting. The paraffin blocks were stored at RT. For sectioning, the moulds were 
mounted on the microtome chuck, sections were cut at a thickness of between 5-7/em, 
mounted onto coated slides, dried at 42°C and stored at RT.
2.11.2 Fixation and embedding of tissues for cryosectioning
Mouse tissues were dissected and either frozen immediately or fixed before being 
frozen (aorta samples were frozen immediately). In the latter case, tissues were fixed in 
4% PFA overnight at 4°C, followed by equilibration of the tissues in cryoprotectant (20- 
30% phosphate buffered sucrose solution) overnight at 4°C. The tissues were then 
placed in embedding moulds filled with Shandon Cryomatrix™ and the moulds were 
gradually frozen on dry ice and stored at -80°C. For sectioning, the moulds were 
mounted on a cryostat chuck and frozen sections were cut at about -26°C at a thickness 
of between 7-10/an. The sections were thaw-mounted onto coated slides and stored at - 
80°C.
2.11.3 Immunohistochemical stainings on paraffin sections
General immunohistochemical stainings used on sections are described here. Additional 
steps were required for stainings using the CD31/PECAM-1 antibody are also included 
and are labelled as such. Slides were subjected to the initial treatments as follows: 2 x 
10 minutes in Xylene, 2 minutes sequentially in 100% ethanol, 95%, 90%, 80%, 70%, 
50%, 25% and finally 5 minutes in PBS. For PECAM-1 stainings, and these additional 
treatment steps were performed as follows: 60 minutes in PBS at 65°, 5 minutes in PBS 
at RT, 10 minutes in 0.3% H20 2 in methanol (all steps from here onwards are performed 
in a humid chamber), 2 minutes in PBS, 12 minutes in 0.1% Trypsin in PBS, 5 minutes 
in 0.1^g/ml Trypsin Inhibitor in PBS, 20 minutes in 2M HCL, and 2 minutes in PBS. 
All stainings proceeded as follows: 30 minutes in blocking solution (1% serum from the 
species in which the secondary antibody was made and 0.1% BSA in PBS), overnight 
incubation in blocking solution containing primary antibodies at 4°C, 3 x 5  minutes in
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PBS, 60 minutes in blocking solution containing secondary antibodies, 3 x 5  minutes in 
PBS, 5 minutes in DAPI solution (nuclear marker, stock at lOmg/ml, 1:1000 dilution in 
PBS), 2 x 5  minutes in PBS. Coverslips were mounted onto the tissue using 
Vectashield® or Mowiol®.
2.11.4 Immunohistochemical stainings on paraffin sections using the 
Batlle Protocol
Detection of ephrinB2, EphB2, EphB3 and EphB4 on paraffin sections was performed 
with goat anti-EphrinB2 (1:200), goat anti-EphB2 (1:200), goat anti-EphB3 (1:200), 
and anti-EphB4 (1:400) antibodies (all from R & D  Systems), based on the protocol as 
described in Batlle et al., 2002, with modifications. In brief, following dewaxing and 
hydration, sections were pretreated with peroxide blocking buffer (120 Na2H P04, 43 
mM citric acid, 30 mM NaN3, 0.2% H20 2, pH 5.8) for 20 minutes at RT. Antigen 
retrieval was performed by boiling the samples in Na-citrate buffer (10 mM, pH 6.0) for 
20 minutes. After boiling, the samples were allowed to cool down slowly to RT. 
Incubation of antibodies was performed in 1% BSA in PBS overnight at 4°C. A 
bridging step was applied through the incubation of the samples in the rabbit anti-goat 
antibody for an hour at RT. This was followed by a 30 minute incubation at RT, in the 
anti-rabbit HRP-conjugated polymer supplied in the Envision+ kit (Dako). Stainings 
were developed for 6 minutes at RT using the peroxide substrates including tyramide- 
FITC and tyramide-Cy3.
2.11.5 Immunohistochemical stainings on cryosections
Slides were transferred from -80°C directly into 100% methanol at RT and fixed for 10 
minutes. The slides were then air dried and washed in PBS ( 2 x 5  minutes). Applying 
the PAP-pen created a barrier surrounding the sections. The tissues on the slides were 
blocked with 2% BSA in PBS for 30 minutes at RT. This was followed by the 
incubation of tissues with the primary antibodies (diluted in blocking solution) for 2 
hours at RT. The slides were washed with PBS ( 3 x 5  minutes) and then incubated with 
secondary antibodies (diluted in blocking solution) for 1 hour at RT, followed by 
another wash with PBS ( 3 x 5  minutes). The tissues were counterstained with the 
nuclear marker DAPI (lOmg/ml, 1:1000 dilution in PBS) for 5 minutes at RT. Slides
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were finally washed in PBS ( 2 x 5  minutes) and the tissues were mounted onto the 
coverslips with Vectashield® or Mowiol®.
2.11.6 Whole-mount immunohistochemistry with PECAM-1 antibody
This procedure was only required for whole-mount embryos using PECAM-1 antibody 
and was performed as follows. Embryos were dissected and fixed in 4% PFA overnight. 
The embryos were then subjected to the following treatments: 3 x 5  minutes in PBS, 
sequential dehydration for 15 minutes each in 25%, 50%, 75%, 100% methanol in PBS 
(embryos can be stored in 100% methanol at -20°C), 5 hours in 5% H20 2 in methanol 
(changing solution every hour), 2 x 15 minutes in 100% methanol, sequential 
rehydration for 15 minutes each in 75%, 50%, 25% methanol in PBS, 2 x 15 minutes in 
PBS, 2 hours in PBSMT (3% non-fat dry milk powder and 0.1% TritonX-100 in PBS), 
overnight incubation with PECAM-1 antibody diluted in PBSMT at 4°C, 5 x 1  hour 
washes in PBSMT at 4°C, overnight incubation with biotinylated secondary anti-rat 
antibody (diluted in PBSMT) at 4°C, 5 x l hour washes in PBSMT at 4°C, overnight 
incubation in ABC-Reagent (Avidin-Biotin Complex- 1:100 in PBSMT) at 4°C, 5 x 1  
hour washes in PBSMT at 4°C, 1 hour in PBT (0.2% BSA and 0.1% TritonX-100 in 
PBS) at RT, incubation of embryos in DAB staining solution (DAB Staining Kit) in the 
dark at RT until sufficient stainings have occurred, 2 x 10 minutes in PBT, 2 x 10 
minutes in PBS, overnight fixation in 4% PFA at 4°C, 3 x 5  minutes in PBS, 1 hour 
clearing in 50% glycerol in PBS, followed by transfer to 70% glycerol in PBS and 
storage at 4°C.
2.11.7 Whole-mount immunofluorescent staining of skin
Whole-mount skin samples were fixed in 4% PFA overnight, washed in PBS and 
gradually dehydrated to 100% methanol. This was followed by gradual rehydration in 
PBS and then incubation in 10% goat serum in PBS containing 0.1% TritonX-100 
(PBX) for 2 hr at 4°C. Samples were incubated with primary antibodies in the same 
solution, overnight at 4°C with gentle agitation. They were then washed five times for 1 
hour each in PBX, followed by overnight incubation with secondary antibodies, at 4°C 
in 10% goat serum in PBX. They were then washed five times for 1 hour as before, in 
PBX. The samples were mounted in-between glass slides and coverslips using
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Vectashield® or Mowiol® mounting medium. The slides were flattened with a weight 
and finally analysed on a Leica microscope or a Zeiss LSM510 Meta confocal 
microscope.
2.11.8 LacZ staining for the detection of P-galactosidase activity in 
transgenic tissues
Whole embryos (stages E9.5 to 13.5) or tissues and organs of both embryos and adults 
were dissected and fixed in LacZ fix solution (0.2% glutaraldehyde, 5mM EGTA, 2mM 
MgCl2 in PBS) for 10-15 minutes, at room temperature on a rocker. The samples were 
washed several times ( 3 x 5  minutes) in wash buffer (2mM MgC12, 0.02% NP-40 in 
PBS). They were then incubated in LacZ staining buffer (containing 1 mg/ml X-Gal, 
2.12mg/ml potassium ferrocyanide, 1.64mg/ml potassium ferricyanide in wash buffer) 
at 37°C, until the desired level of staining had been obtained. The samples were then 
washed twice in PBS, post-fixed with 4% PFA overnight and stored in PBS at 4°C.
2.11.9 Embedding of lacZ-stained tissue
As LacZ stainings tends to fade away during dehydration and Xylene treatments, the 
incubation times in the different solutions were reduced as follow: 15 minutes in 0.9% 
NaCI in 50% ethanol at RT, 2 x 15 minutes 70% ethanol in PBS at RT, 30 minutes in 
85% ethanol in PBS at RT, 30 minutes in 95% ethanol in PBS at RT, 2 x 45 minutes in 
100% ethanol at RT, 2 x 30 minutes in Xylene at RT, 30 minutes in Paraffin/Xylene 
(1:1 ratio) at 56°C, 4 x 60 minutes in Paraffin at 56°C. The samples were transferred 
into embedding moulds filled with hot paraffin and allowed to solidify overnight at RT.
2.11.10 Preparation of embryo powder
Embryo powder was needed to preabsorb the Anti-Digoxigenin-AP antibody used for in 
situ hybridisations and was prepared as follows. A litter of E12.5 embryos were 
dissected and homogenised in a minimum amount of cold PBS, using a pestle and 
mortar. Four times the volume of ice cold acetone was added, vortexed and placed on 
ice for a further 30 minutes. The sample was centrifuged at 10,000 RPM at 4°C for 10 
minutes and the floating remains were removed with the supernatant. After rinsing the
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pellet with ice-cold acetone, it was placed on filter paper to air dry completely. This was 
then ground to powder using a pestle and mortar and stored at -20°C.
2.11.11 Whole-mount in situ hybridisation with ephrinB2 riboprobes
For the generation of digoxigenin-(DIG)-labelled RNA probes for in situ hybridisation, 
a construct containing a 890 bp fragment of ephrinB2, extending from nucleotide 4 to 
890 (extracellular domain), was linearised to prepare antisense and sense RNA probes. 
The probes were synthesised with a DIG RNA Labelling Kit (Roche) according to the 
manufacturers instructions. Dissected E9.5 embryos were fixed overnight in 4% PFA 
and gradually dehydrated in 100% methanol and stored at -20°C. For whole-mount in 
situ hybridisation of ephrinB2 Riboprobes on E9.5 embryos, the procedure is briefly 
described here. Embryos were gradually rehydrated in 75%, 50%, 25% methanol in 
PBS (15 minutes each) and then subjected to the following treatments: 2 x 5  minutes 
washed in PBT (0.1% Tween-20 in PBS) at RT, 1 hour bleaching in 6% H20 2 in PBT at 
RT with rocking, 3x 5 minutes washes in PBT at RT, a 15 minute treatment with 
10//g/ml Proteinase K in PBT at RT with rocking, a 10 minute wash with 2mg/ml 
glycine in PBT (freshly made) at RT with rocking, and 2 x 5  minute washes in PBT at 
RT. Embryos were transferred to 2 ml tubes and 1ml of Prehybridisation Solution 
(Prehyb.- 50% Formamide, 5x SSC (pH 4.5), 50/*g/ml yeast RNA, 1% SDS, 50/*g/ml 
Heparin) was added and incubated at 70°C for 1 hour. Hybridisation Solution (Prehyb. 
with ~l/<g/ml DIG Riboprobe) was made up and kept at 37°C. Prehyb. was then 
aspirated and replaced with 1ml Hybridisation solution and allowed to hybridise 
overnight at 70°C. The following wash steps were done as follows: 3 x 30 minute 
washes in pre-warmed Solution 1 (50% Formamide, 5x SSC (pH 4.5), 1% SDS) at 70°C 
with rocking, 3 x 30 minute washes in Solution 3 (50% Formamide, 2x SSC (pH 4.5)), 
3 x 5  minutes washes in fresh TBST (1% Tween-20 and 2mM Levimasole) at RT with 
rocking, 2.5 hours in blocking solution (10% sheep serum in TBST) at RT with rocking. 
In the meantime the antibody solution was prepared as follows: In a 2ml tube, 0.5ml of 
TBST and 3mg of embryo powder was added and rocked for 30 minutes at 70°C. The 
sample was vortexed for 10 minutes, then cooled on ice. After adding 5/<l sheep serum 
and 1/d of Anti-Digoxigenin-AP antibody, it was rocked for 1 hour at 4°C, followed by 
a centrifugation at 13,000 RPM at 4°C for 10 minutes. The supernatant was collected 
into a 15ml tube and diluted with 1% sheep serum in TBST to bring the volume up to 
2ml, followed by a 10 minutes centrifugation at 4,000 RPM at 4°C. The blocking serum
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was removed from the embryos and 1ml of antibody mix was added and mixed gently. 
This was then removed and an additional 1ml of antibody mix was added and incubated 
overnight at 4°C with rocking. The post antibody hybridisation washes were carried out 
as follows: 3 x 5  minute washes in TBST at RT with rocking, 5 x 1  hour washes in 
TBST at RT with rocking, overnight wash in TBST at 4°C with rocking. For the 
detection steps, the following procedures were followed: 3 x 10 minute washes in 
NTMT (1% Tween-20 and 2mM Levimasole) at RT with rocking, followed by 
incubation of embryos in staining solution (3.5/d BCIP (Roche) and 4.5/d NBT (Roche) 
in 1ml NTMT) in the dark with rocking until sufficient staining levels was achieved. 2 x 
10 minute washes in PBT were performed at RT with rocking, followed by overnight 
fixation in 4% PFA at 4°C, then 2 x 5  minute washes in PBT and stained embryos were 
finally stored at 4°C.
2.11.12 Selection for YFP positives cells from embryonic skin using 
FACS
Timed matings were set up between PDGFRp-Cre and Rosa26R lines. Yellow 
Fluorescent Protein (YFP) expressing embryos at E l 8.5, due to Cre mediated 
recombination, were easily identified by using a UV lamp under the microscope, using 
a GFP filter. The skin of these embryos were dissected out and incubated for 2 hours at 
37°C, in a 5ml solution containing 2.5ml Collagenase (0.2//M) and 2.5ml of 2x Trypsin 
solution, supplemented with 3/*M EDTA in PBS. The solution was then neutralised by 
adding 10ml of 10% Foetal Calf Serum (FCS) in DMEM (complete media) and 
incubating for 2 minutes. After a 1,000 RPM spin in a centrifuge for 5 minutes, the 
eluate was passed through a sieve with a pore size of 100/<m (removing cell clumps and 
debris) and collected. An additional 5ml of complete media was passed through the 
sieve and the total collected sample was centrifuged at 1,000 RPM for 5 minutes, after 
which the supernatant was decanted and the remaining cells were resuspended in 3 ml 
of DMEM containing 2% FCS. This sample was then given to the Fluorescence 
Activated Cell Sorter Department where they sorted and collected YFP expressing cells.
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2.12 In vitro analysis of isolated mouse cells
2.12.1 Aortic ring assay
The aorta was isolated from E l8.5 ephrinB2l0X/+ mice embryos and placed in lx  E4 
medium for dissection. The fibroadipose tissue was removed followed by the removal 
of the tunica adventitia layer. The aorta was then cut at l-2mm intervals to obtain aortic 
rings and these were used for cultures according to the methodology of Bonanno et al. 
(2000) with modifications (unpublished). Briefly, the matrix used consisted of 30/<g/ml 
Collagen Type IV, lmg/ml Collagen Type I, 15//M NaOH, lOx E4 media, with 
appropriate amount of water. 250/d of this collagen mix was added to each well of a 4- 
well dish and left at 37°C for ~ 15 minutes to set. Each ring was stuck to the surface of 
the wells using 2/d of the liquid collagen mix, placed in a 37°C incubator for 5 minutes 
for the ring to adhere to the matrix and finally, 250/d of 10% FCS DMEM, 
supplemented with L-glutamine and penicillin/streptomycin, were added. The medium 
was replaced every two days.
2.12.2 Selection of endothelial cells using Dynabeads CD31
Cells that sprouted from the aortic ring assay were selected for endothelial cell 
populations using the Dynabeads® CD31 (Dynal Biotech) according to the 
manufacture’s instructions.
2.12.3 Culturing smooth muscle cells isolated from the aorta
The “immorto” mice, where cells could be immortalised using the temperature sensitive 
SV40 antigen, were used for deriving SMCs. The aorta was isolated from the adult 
progeny, placed in DMEM and the adventitial layer removed. The aorta was cut 
longitudinally into ~ 5mm x 5mm pieces and placed into a 6-well dish, with the lumen 
touching the plastic. 10% FCS DMEM supplemented with 50u/ml IFNy, was then 
added and cultured at 33°C. Once a significant number of cells had sprouted out 
(potententially SMCs), the aorta pieces were then removed, and the remaining cells 
were propagated in the same culturing conditions. These resulting cells were checked 
for their smooth muscle cell identity by staining with the aSM A antibody.
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2.12.4 Aortic piece assay for assessing SMC sprouting and migration in 
response to PDGF-B
Mutant and control embryos were harvested at E l 8.5 and their aortas were dissected out 
in DMEM. Once the adventitial layers were removed, the aortas were cut longitudinally 
into ~ 5mm x 5mm pieces and placed into 4-well dishes coated with 250/^g/ml of 
Collagen I, with the lumen side in contact with the matrix. The well was then filled with 
200/<l of DMEM supplemented with 0.5% foetal calf serum and 20ng/ml of soluble 
PDGF. The aortic pieces were then examined and followed for levels of sprouting and 
migration differences between mutants and controls.
2.13 Preparation of Tamoxifen and 4-Hydroxytamoxifen
In vials containing Tamoxifen and 4-Hydroxytamoxifen powder, peanut oil was added 
to obtain a concentration of 1 mg/ml. The vials were placed in a beaker with ice, and 
then subjected to sonication (Sanyo Soniprep 150) at a frequency of 10 kHz for a total 
of 5 minutes at one minute intervals to allow the solution to cool. This was then stored 
at 4°C.
2.14 Electron microscopy
Skin samples were fixed in 2.5%glutaraldehyde in Sorensens Phosphate buffer pH 7.4, 
post fixed in Osmium tetroxide in the same buffer and given to the Electon Microscopy 
Unit for processing. In brief, the samples were embedded in araldite, sections were cut 
on a Reichert Ultracut, stained with lead citrate and uranyl acetate and viewed in a 
JEOL 1010.
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Chapter3 I Investigating the role of ephrinB2
in endothelial cells
3.1 Introduction
The cardiovascular system is the first organ system to develop and reach a functional 
state during embryonic development. “Vasculogenesis” refers to the initial steps when 
the endothelial cell precursors, the angioblasts, are differentiated from the mesenchyme 
to form a juvenile vascular system (Risau and Flamme, 1995). This primary capillary 
plexus is subsequently remodelled into a mature vascular system by pruning and 
reorganisation of endothelial cells in a process called “angiogenesis”. This complex 
remodelling process involves the recruitment of mural cells to stabilise the vessels and 
starts in the vasculature of many organs during late embryonic development (Nehls and 
Drenckhahn, 1993), but the molecular mechanism is poorly understood.
3.1.1 The Cre-loxP System
Vascular defects and arrested morphogenesis in knockout mice has led to the 
identification of several important signalling molecules and pathways that regulate 
blood vessel formation processes. A frequent limitation in such studies is that null 
mutants are embryonic lethal at E9.5-E11 or exhibit complex phenotypes that do not 
allow the identification of the function of the investigated gene during vascular 
development. These limitations can be overcome by cell-type specific and inducible 
gene targeting systems such as the Cre-loxP approach, which exploits the site-specific 
recombinase activity of a gene product from bacteriophage PI (Vasioukhin et al., 1999; 
Branda and Dymecki, 2004). The 38 kDa “Cre” recombinase specifically recognises the 
34 bp sequences termed “loxP” sites. The system requires the crossing of two mouse 
lines, one that carries the target with an insertion of two loxP sites (known as “floxed”), 
while the other line expresses Cre recombinase under the control of a cell/tissue specific 
promoter and may be inducible. Consequently, Cre activity and gene activation will be 
restricted to specific cell-types or tissues (Figure 3.1). The first step of this approach 
involves the insertion of the loxP flanked targeting construct into a specific gene locus
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by homologous recombination in embryonic stem (ES) cells. The construct contains a 
selection marker, usually the neomycin phosphotransferase (Neo) gene, to facilitate the 
identification of ES cells where recombination has occurred. However, selection 
markers may interfere with the normal transcription and splicing of the targeted and 
neighbouring genes, and may affect or compromise protein expression (Ohno et al., 
1994). A widely used method to avoid such effects is to flank selection markers with 
“Frt” recognition sites and to remove them using “Flp”, a recombinase from the yeast 
Saccharomyces cerevisiae (Dymecki, 1996).
Even though the Cre/loxP system is a powerful tool for manipulating the mouse, it has 
its own intrinsic limitations, predominantly due to the fact that it relies on a partial 
promoter sequence (possibly enhancers as well) to drive Cre expression. Inappropriate 
or unexpected Cre expression may lead to recombination in cell-types other than the 
desired ones. The intrinsic nature of a promoter and its regulation will affect the 
temporal and spatial pattern of recombination. Complications may also arise in complex 
breeding schemes where multiple conditional alleles need to be combined with specific 
transgenes. Cre expression and activity can be monitored using Rosa26R reporter 
mouse line where a triple polyadenylation sequence is flanked by loxP sites that is fused 
to the lacZ  sequence and integrated in the Rosa26 locus (Soriano, 1999), a site in which 
promoter elements lead to ubiquitous expression. Breeding of these mice with specific 
Cre lines enables the monitoring of the activity and timing of Cre mediated 
recombination in vivo because the deletion of the loxP-flanked triple polyadenylation 
sequence results in constitutive p-galactosidase expression.
A limitation of the Cre-loxP system is the lack of control over the onset of Cre 
expression. This is particularly important if gene inactivation occurs early in 
development and leads to defects that will compromise other developmental processes 
without a direct involvement of the targeted gene. Such problems can be addressed by 
temporal regulation of Cre recombinase in vivo. This can be accomplished with 
tetracycline controlled gene expression systems, interferon-inducible expression or drug 
inducible forms of Cre (Garcia and Mills, 2002). In the latter case, the ligand binding 
domain of a mutated human oestrogen receptor is fused to Cre (CreERT), so that the 
fusion protein requires the administration of the synthetic oestrogen antagonist
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tamoxifen (or its derivative 4-hydroxytamoxifen) for its translocation into the nucleus 
and consequently, elimination of the loxP-flanked sequence (Figure 3.1)(Zhang et al., 
1996).
3.1.2 Previous studies on ephrinB2
EphrinB2 marks arterial endothelial cells from the onset of angiogenesis during mouse 
embryonic development and is an important regulator of blood vessel development. 
Mice lacking ephrinB2 (ephrinB2K0/K0) are lethal by midgestation (E l l)  and display 
angiogenic remodelling arrest in the head and yolk sac and defective myocardial 
trabeculation in the heart (Wang et al., 1998; Adams et al., 1999). As development 
proceeds, its expression progressively extends from the arterial endothelium to 
surrounding vascular smooth muscle cells and pericytes (Gale et al., 2001; Shin et al., 
2001). Expression of ephrin-B2 has been shown to be downregulated in many adult 
tissues but is strongly expressed during neovascularisation associated with corpus 
luteum formation, wound healing and tumour angiogenesis (Gale et al., 2001; Shin et 
al., 2001).
Global ablation of ephrinB2 leads to severe cardiovascular defects in embryos, growth 
retardation and midgestation lethality. As multiple cell types in the cardiovascular 
system express ephrinB2, the specific requirement of the gene is difficult to address by 
global gene targeting.
3.2 Results
3.2.1 Generation ephrinB2 Conditional Line
The early lethality displayed by ephrinB2 knockout embryos has limited insight into its 
specific role in vascular morphogenesis. Mutants displayed defective remodeling of the 
yolk sac vascular plexus and decreased branching of cranial capillaries, as well as 
abnormal sprouting of intersomitic vessels and decreased vascularization of the neural 
tube. However, it is possible that some of these defects could be caused by malfunctions
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of the heart and defects in extra-embryonic tissues. It is noteworthy that gene targeting 
of many other genes, including those involved in the Notch, Tie and VEGFR pathways, 
have resulted in very similar phenotypes.
To determine the specific role of ephrinB2 in endothelial cells (ECs), as well as in other 
cell types, a conditional ephrinB2 mouse line has been generated (Figure 3.2)(Grunwald 
et al., 2004) and has been used in the work presented here. Two different ephrinB2 
conditional lines have been used, one contained the Neo cassette (ephrinB2loxNeo/+)> 
whereas Neo  has been excised (ephrinB2,ox/+) by breeding to the Flp deleter mice 
(Dymecki, 1996) in the second line.
As interbreeding of ephrinB2loxNeo/+ heterozygotes did not produce any homozygous 
offspring at weaning age, different stages of embryonic development was investigated 
by timed matings of animals. Freshly dissected ephrinB2loxNeo/loxNeo embryos at E9.5 
displayed growth retardation as well as morphological abnormalities in the head, heart 
and back regions. Whole-mount stainings for PECAM-1, an endothelial cell marker, 
revealed severe vascular malformations such as arrest of vascular remodelling in the 
head, disrupted formation of the posterior cardinal vein and second branchial arch as 
well as inflation of the pericardium (Figure 3.3) These defects are similar to those 
observed in ephrinB2 knockouts. Homozygous mutants for both strains displayed 
similar lethality by E l l  with full penetrance. In summary, the phenotypic similarities 
seen in ephrinB2loxNeo/loxNeo and ephrinB2 null mutants suggest that the presence of the 
Neo cassette in the conditional allele impairs expression of ephrinB2. Accordingly, Flp 
recombinase-mediated removal of Neo  permitted the generation of ephrinB2lox/lox 
homozygotes at the expected ratio so this line was used for subsequent studies.
3.2.2 Validation of the conditional targeting using PGK-Cre
The conditional ephrinB2 line (ephrinB2lox) had to be validated to ensure that the 
floxed-targeted locus was accessible to Cre as a prerequisite for recombinase-mediated 
deletion. For this purpose, the ephrinB2 gene was inactivated globally (ephrinB2A8lobal 
mutants), with the help of a transgenic line expressing Cre in a ubiquitous manner, to 
investigate whether resulting embryos would recapitulate the ephrinB2 knockout
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phenotype. In PGK-Cre mice, Cre expression is driven by the promoter of endogenous 
3-phosphoglycerate kinase (Lallemand et al., 1998). As this enzyme is involved in 
glycolysis necessary for every cell, the PGK promoter is active ubiquitously. Cross­
breeding of the PGK-Cre and ephrinB2l0X/l0X mice allowed the generation of 
ephrinB2Aglobal mutants (Figure 3.4) which were then analysed. Whole-mount stainings 
of E9.5 embryos with anti-PECAM-1 antibody revealed an array of anomalies in 
cardiovascular development and angiogenic remodelling defects in mutants that were 
indistinguishable from ephrinB2K0/K0 embryos (Figure 3.5). ephrinB2Aglobal animals were 
dead by E l l  with full penetrance. Furthermore, whole-mount in situ hybridisation for 
ephrinB2  (efnb2) mRNA in ephrinB2Aglobal mutant embryos showed no detectable 
transcripts (Figure 3.6) and proved that ubiquitous ablation was achieved.
3.2.3 Investigating the role of ephrinB2 in endothelial cells using the 
Tiel-Cre line
To determine the role of ephrinB2 in endothelial cells, ephrinB2lox/lox mice were 
combined with the T iel-C re transgenic line. This line restricts Cre expression and 
activity to the vascular endothelium of vascular structures from stage E8.5 onwards. 
Structures with Cre expression include the dorsal aorta, the yolk sac vasculature, and 
the developing heart tube (Gustafsson et al., 2001). Expression in many different 
vascular beds is also evident at later stages of embryonic development, and persists into 
adulthood. Additionally, sites of expression at later stages of development include the 
glomeruli of kidneys, brain, alveolar capillaries in the lung and endocardial cells lining 
the heart.
Endothelial cell-specific ephrinB2 mutants (ephrinB2AEC) were growth retarded, their 
yolk sacs were pale and they displayed very few blood vessels due to remodelling 
defects (Figure 3.7). Similar defects were seen in ephrinB2Aglobal mutants. PECAM-1 
staining of whole ephrinB2AEC embryos revealed severe vascular anomalies including 
arrested angiogenesis in the head vasculature, defects in the posterior cardinal vein and 
the dorsal aorta, as well as inflated pericardium (Figure 3.5). Nevertheless, mutants 
were alive and displayed a beating heart. Despite these similarities, the phenotype of 
ephrinB2AEC mutants seemed less severe than what has been seen in full knockouts.
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Furthermore, in situ hybridisation for the presence of ephrinB2 mRNA showed an 
overall reduction in transcript levels throughout the ephrinB2AEC embryos in comparison 
to controls, which is presumably caused by the growth retardation evident at E9.5 
(Figure 3.6). EphrinB2 mRNA was absent in the larger vessels, intersomitic vessels and 
the dorsal aorta. EphrinB2 transcripts in the mutant head region and in the branchial 
arches appear to correspond to expression in neural crest and mesenchymal cell 
populations.
3.2.4 Inducible ephrinB2 ablation in endothelial cells with Tie2- 
CreERT transgenic
As the lethality of ephrinB2AEC mutants prevents studies in late embryos and adults, it 
was impossible to study the role of the ligand in most tissues and organs. To circumvent 
this problem, a previously uncharacterised inducible endothelial-specific Tie2-CreERT 
line (E. Wagner, unpublished) was acquired. This line hosts a transgene in which Cre 
was fused to the hormone-binding domain of oestrogen receptor (ERT) that has been 
modified so that it can only be activated by binding of tam oxifen or 4- 
hydroxytamoxifen. Since the inducible Tie2-CreERT mice had not been sufficiently 
characterised, the line was bred into a Rosa26R Cre reporter background to study its 
suitability for gene inactivation experiments.
3.2.4.1 Characterisation of Tie2-CreERT activity in embryos
To study Tie2-CreERT activity in mouse embryos, single intraparitoneal injections of 
either tamoxifen or its more potent metabolite 4-hydroxytamoxifen (40H-TM ) were 
administered to females at different stages of pregnancy (E9.5 to E17.5). The injected 
concentration was 5mg/40g body weight, which is and significantly below the reported 
lethal dose (Hayashi and McMahon, 2002). Embryos were harvested 24 hours post 
injection and assayed for P-galactosidase expression as a measure of Cre activity. This 
regime did not lead to detectable lacZ staining and no obvious adverse effects due to 
toxicity were noticed (data not shown).
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In a second approach, 40H-TM , at a dose of 3mg/40g body weight, was administered 
by intraperitoneally injection for three days in succession. This regime was applied to 
female mice at different stages of gestation starting from E9.5. Embryos were collected 
24 hours after the final injection and subjected to P-galactosidase stainings. Even 
though the analysis revealed barely detectable levels of p-galactosidase activity for the 
vast majority of the embryos (data not shown), mosaic vascular staining was obtained 
for a fraction of double transgenic embryos. Of these samples, one embryo at E l 1 in 
particular, displayed widespread staining in blood vessel-like structures (Figure 3.8). As 
some embryos showed signs of growth retardation or oedema and because of an 
increased incidence of reabsorption (data not shown), it appears that toxic effects caused 
by the triple injection regime are more significant than for single injection.
3.2.4.2 Induction of Tie2-CreERT activity in adult mice and in tumours
The Tie2-CreERT line was also assessed for its capability of inducing Cre expression in 
adults. For this purpose, regimes of three or five injections of 5mg/40g body weight of 
40H-TM , spaced by 24-hour intervals, were administered intraperitoneally in 12 week 
old mice. The mice were sacrificed 24 hours after the final injection and isolated organs 
and tissues were assayed for lacZ expression, but revealed no specific staining in lung, 
kidney, heart, aorta, skin or intestine (data not shown). Several of the sacrificed animals 
had discoloured livers indicative of side effects. It has been reported that tamoxifen is 
converted into a-hydroxytamoxifen in the rodent liver where it can cause damage and 
induce hepatocarinomas if administered chronically (Wogan, 1997), which may explain 
the observation above.
Alternatively, “timed release” pellets from Innovative Research of America were 
implanted subcutaneously to induce Cre expression. This application route presents 
several advantages: a) animals are only exposed to the stress of a single implantation 
procedure, b) “peak and valley” effects are avoided, and c) rapid removal of tamoxifen 
through metabolic processes is prevented. Animals that had received lOOmg of 
tamoxifen over a period of 22 days were sacrificed and various organs were analysed 
for P-galactosidase activity. Blue staining indicative of EC-specific Cre activity was 
observed in various tissues and organs (Figure 3.9), including heart, aorta, lung and tail
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skin. Thus, timed release pellets are, in principle, suitable for the induction of Cre 
activity in adult tissues and organs. Furthermore, no toxic effects were observed.
To investigate whether the Tie2-CreERT line could be used for studies in the tumour 
vasculature, Tie2-CreERT/Rosa26R double transgenic mice received timed release 
pellets and, with a delay of three days, a single subcutaneous injection of two million 
Lewis Lung Carcinoma cells. These mice had to be sacrificed 11 days after the injection 
of the cells because tumours had grown to a size of 150-200 mm3, close to the legal 
limit of 250 mm3. The analysis of dissected tumours revealed lacZ expression that 
corresponds to a population of small vessels and capillaries (Figure 3.9). However, Cre 
induction appeared incomplete and this approach was not pursued any further.
3.3 Discussion
The early lethality displayed by ephrinB2 null embryos has limited the study of its role 
in blood vessel morphogenesis and development. From the analysis of the knockouts, it 
is difficult to determine whether the vascular defects are independent from the 
aberrations in the heart and extra-embryonic tissues. The Cre/loxP system may permit 
cell type-specific deletion of the ephrinB2 gene to study specific roles of the ligand. To 
establish the suitability of an ephrinB2l0X conditional line for experimental studies, these 
mice were bred to PGK-Cre transgenics expressing Cre ubiquitously. The resulting 
ephrinB2A8lobal mutants were lethal by E l 1 and displayed vascular malformations that 
were indistinguishable from the ephrinB2 knockout phenotype. In addition, in situ 
hybridisation of whole ephrinB2Aglobal embryos confirmed the absence of ephrinB2 
mRNA suggesting that its ubiquitous ablation was achieved. The data validated the 
suitability for tissue-specific gene inactivation experiments. Furthermore, Grunwald and 
colleagues have also successfully used this line to remove ephrinB2 in the developing 
nervous system and in postnatal forebrain with Nestin-Cre and CamKIIa-Cre transgenic 
lines, respectively (Grunwald et al., 2004).
To investigate the role of ephrinB2 in the endothelial lining of blood vessels, the 
conditional line was bred with EC-specific Tie 1-Cre transgenics. EphrinB2AEC mutant 
embryos were lethal by E l l  and displayed cardiovascular defects similar to null
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mutants. Some ephrinB2AEC mutants displayed a less severe phenotype, which could be 
due to incomplete deletion of the loxP-flanked ephrinB2 gene fragment in the EC 
population. Similar work with a different EC-specific Cre, published by Gerety and co­
workers, showed that mutants were phenotypically indistinguishable from global 
ephrinB2 knockouts (Gerety and Anderson, 2002). However, the mutants generated by 
Gerety and colleagues harbour only one conditional allele in a null background. 
Therefore Cre-mediated recombination had to occur at only one allele leading to 
increased chances for a complete deletion in the endothelium. On the other hand, some 
abnorm alities in these mutants could be caused or enhanced due to the 
haploinsufficiency of ephrinB2 expression in cell populations outside the endothelium, 
independent of Cre mediated recombination. Defects seen in ephrinB2loxNco 
homozygotes support that hypomorphic phenotypes can be caused by reduced ephrinB2 
expression. The results presented here showed that ephrinB2 expression in endothelial 
cells is essential for normal development. The role of cardiac defects or changed 
haemodynamic parameters remains to be determined.
To avoid the early lethality of ephrinB2AEC mutants and address the role of ephrinB2 in 
the late embryonic and adult vasculature, the previously uncharacterised inducible Tie2- 
CreERT line was acquired, and bred into Rosa26R Cre reporter background. Single or 
multiple intraperitoneal injections of pregnant females from timed matings with either 
tamoxifen or 40H-TM  resulted in poor Cre activity that was considered insufficient for 
functional studies. Likewise, CreERT activation in adult tissues and organs could not be 
achieved by 40H-TM  injection.
The application of tamoxifen through timed release pellets led to lacZ expression in 
various vascular beds, especially in the coronary vessels of the heart. This suggests that 
the continuous release of tamoxifen over a longer period of time produces better results 
than injection schemes. Nevertheless, reporter activation in the endothelium of adult 
tissues and in xenograft tumours was incomplete and, presumably, too low for 
functional studies with the ephrinB2Iox line.
These results might be caused by a limited capability for Cre induction of the Tie2- 
CreER7 line. Successful inducible gene inactivation in the adult endothelium has not 
been reported so far and is a major technical challenge in the field. The application
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regime and biological availability of tamoxifen or 40H -TM  are further factors that 
could influence the activation of CreERT in transgenic mice. In fact, recent work from 
the laboratory shows that a modified protocol of tamoxifen preparation and injection 
leads to significantly improved reporter activation in Tie2-CreERT/Rosa26R double 
transgenics.
The studies described here have also highlighted the toxicity of high doses of tamoxifen 
and 40H -TM  in embryonic and adult mice, a side effect that can have significant 
impact on functional studies. Peanut oil, in which tamoxifen and 40H -TM  was 
suspended, may also contribute to the toxicity and little is known about its effects in 
systemic administration. No systemic toxicity was noticed in adult mice with pellet 
implantations indicating that the absence of oil or other carrier substances, along with 
the longer lasting application of lower tamoxifen doses, might be beneficial. Further 
work is needed to address this question.
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Figure 3.1: Generation of cell type specific knockouts using the Cre/loxP
conditional system
Mice expressing Cre (a) or CreER (c) in specific cell types are bred with mice 
containing a target gene fragment flanked by loxP sites (b). In the Cre 
containing progenies (d), Cre expressing cells will mediate gene fragment 
deletion through recombination. While in the CreER containing progenies (e), 
Cre expression should only occur upon tamoxifen administration, thereby 
mediating cell type specific deletion.
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Figure 3.2: EphrinB2 conditional targeting vector and different
recombination events
Schematic representation of the ephrinB2 conditional targeting vector. The loxP 
and Frt sites flank exon-2 and the neomycin (Neo) resistance selection marker 
respectively (a). Crossing with the Flp recombinase mice removed the Neo 
cassette (b). Cell type-specific deletion of the ephrinB2 fragment mediated by 
breedings with various Cre lines (c).
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Figure 3.3: Homozygous ephrinB2loxNeo display vascular defects that are 
similar to the ephrinB2 knockouts
PECAM-1 staining on whole-mount embryos at E9.5 embryos labelling the 
vascular network. The vascular morphology of the ephrinB2loxNeo/+ mutants (b) 
is indistinguishable from wildtype controls (a). EphrinB2loxNeo/loxNeo mice (c) 
displayed severe defects in blood vessel development that were similar to 
those seen in the ephrinB2 knockout (d). Malformations disrupted assembly of 
the posterior cardinal vein (arrow) and second branchial arch (arrowhead) as 
well as causing defective angiogenic remodelling in the head region (asterisk).
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Figure 3.4: Breeding scheme for the generation of ephrinB2Aglobal
The scheme illustrates the breeding steps required to generate ephrinB2Aglobal 
embryos. A similar breeding scheme was used for the generation of tissue- 
specific ephrinB2 mutants with various transgenic lines.
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Figure 3.5: Global and endothelial cell-specific deletion of ephrinB2 leads to 
vascular defects and lethality by E11
PECAM-1 stained whole embryos at E9.5 revealing the different vascular 
morphology of ephrinB2 mutants. Blood vessel morphology is severely disrupted 
in ephrinB2A9|obal (c) and ephrinB2AEC (d) embryos compared to littermate controls 
(a). These defects are similar to those displayed by ephrinB2 knockout mice (b) 
and include defects in remodelling of blood vessels in the head regions 
(arrowheads) and formation of posterior cardinal veins (arrows).
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Figure 3.6: Absence of ephrinB2 mRNA transcripts in ephrinB2A9|obal 
mutants and a partial decrease in ephrinB2AEC mutant
In situ hybridisation of whole embryos at E9.5 for the detection of ephrinB2 
mRNA transcripts. No detectable staining was obtained for ephrinB2A9lobal 
mutants (b), while ephrinB2AEC embryos displayed reduced ephrinB2 
expression (c) in comparison to controls (a). EphrinB2 mRNA (efnb2) was 
absent in the ephrinB2AEC vasculature but not in the branchial arches (arrows) 
and head regions (arrowheads). Overall, transcription levels in ephrinB2AEC 
mice appeared reduced, presumably due to growth retardation at E9.5.
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Figure 3.7: Blood vessel defects in the yolk sacs of ephrinB2A9lobal and
ephrinB2AEC mutants
Images taken from freshly dissected E9.5 embryos with intact yolk sacs. In 
both ephrinB2A9lobal (b) and ephrinB2AEC (c) mutants, the vitelline vessels 
and associated branches were absent. A control is shown in (a).
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Figure 3.8: LacZ staining of Tie2-CreERT/Rosa26R double heterozygous 
embryos reveal blood vessel structures upon 40H-TM administration
Pregnant females were subjected to the triple-injection regime of 40H-TM. 
LacZ staining on Tie2-CreERT/Rosa26R double heterozygous E11 embryo 
revealed different vascular structures including the vascular branching in the 
head region (b,c- asterisks), the vessels in the branchial arches (d- 
arrowhead) and the intersomitic vessels (d- arrows). Blue staining was 
absent in littermate controls (a).
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Figure 3.9: Induction of Tie2-CreERT in adult organs, tissues and tumours
Tie2-CreERT adults in a Rosa26R background were implanted with tamoxifen 
timed release pellets. LacZ expression in a range of harvested tissues and 
organs revealed induction of CreERT activity in several vascular structures (a, 
arrowheads). Blue staining was absent in the controls. LacZ staining of Lewis 
Lung Carcinoma tumour cells in Tie2-CreERT/Rosa26R transgenic mice, followed 
by pellet implantation, led to blue staining in structures that may correspond to 
small intratumour vessels and capillaries (b). Sections (7pim) have been 
counterstained with eosin.
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Chapter4 I Characterisation of SMMHC-Cre 
mice, generation and characterisation of 
mural ceils specific Cre transgenic line
4.1 Introduction
Mural cells are involved in complex interactions with both the endothelial lining of 
blood vessels and the surrounding extracellular matrix. They play important roles 
during embryonic development, which range from the stabilisation of nascent vessels, 
the inhibition of EC proliferation and angiogenesis, to the modulation of the blood flow 
(Carmeliet, 2000).
Shin and co-workers (Shin et al., 2001) have demonstrated that ephrinB2 expression 
extends from the arterial endothelium to vSMCs during late embryonic development 
and in adults. However, the function and requirement of ephrinB2 in mural cell 
populations has yet to be elucidated. To enable the inactivation of ephrinB2 in mural 
cell populations with the Cre-loxP approach, a transgenic line expressing Cre 
selectively in vSMC/pericyte populations was required. Many investigators have 
experienced great difficulties in generating such a line, largely due to the fact that many 
smooth muscle promoters are only transiently active during development or are used by 
other cell types, for example, in the heart and somites (Edelberg et al., 1998; Hirota et 
al., 1999). These problems have previously limited the generation of suitable tools for 
SMC-specific inactivation studies in vivo.
4.2 Results
4.2.1 Characterisation of SMMHC-Cre mice
Regan and co-workers (Regan et al., 2000) reported the generation of a transgenic line 
expressing Cre under the smooth muscle myosin heavy chain promoter (SMMHC-Cre). 
With the help of Rosa26R Cre reporter mice, they showed that their line expressed Cre
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as early as E l2.5 in aortic and airway SMCs. In later stages of embryonic development, 
expression progressively increased in smaller vessels and other SMC-containing tissues 
such as the intestine and heart. They reported that SMC-restricted expression persists in 
adult mice and includes blood vessels in skeletal muscle, the carotid arteries and 
numerous other organs such as the oesophagus, trachea and ureter.
Initial experiments were designed to reproduce the published data on the SMMHC-Cre 
line and in particular, the induction of Cre expression in SMC populations during 
embryonic development. The line was bred into the Rosa26R background and resulting 
embryos were assayed for P-galactosidase activity. The analysis at various embryonic 
stages ranging from E12.5 to E17.5 did not reproduce the reported staining patterns 
(data not shown). Consequently, it was concluded that this line could not be utilised to 
elucidate the role of ephrinB2 in vSMCs during embryonic development.
4.2.2 Generation of the PDGFRp-LacZ and PDGFRp-Cre line and 
determining their expression patterns
The difficulties with the SMMC-Cre line described above prompted the attempt to 
generate a new SMC-specific Cre line. Cre expression under the control of a PDGFR|3 
promoter fragment was decided upon because this receptor is a common marker for 
SMCs, pericytes and their progenitors (Hellstrom et al., 1999). To evaluate whether this 
genomic fragment that was 13Kb in size and covered exons 3 to 6 of the PDGFRfJ gene, 
contained the necessary regulatory elements for expression in SMC populations, a 
PDGFRp-LacZ reporter construct was generated. An internal ribosomal entry site 
(IRES) was fused to a LacZ cDNA (IRES-LacZ), followed by the SV40T 
polyadenylation signal and inserted into exon 4  of the PDGFR|3 genomic fragment 
(Figure 4.1). When transient transgenic experiments by pronuclear injections into 
mouse embryos indicated that the PDGFRp gene fragment permitted P-galactosidase 
expression in blood vessels (Figure 4.2), several founder lines were generated and tested 
in greater detail. Of the 12 lines tested, two exhibited staining correlating to vSMCs. 
The line with better expression, referred to as PDGFRfMacZ, showed high level of 
staining in blood vessels at E12 and E l3.5 (Figure 4.2) as well as in later stages of 
embryonic development. At E l 8.5, vascular structures in various vascular beds,
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including the mesenteric vessels of the intestine, blood vessels in meninges and skin, 
and the mesangial cells of the kidney glomeruli, were stained (Figure 4.3). Very little 
lacZ expression was visible outside the vascular system although PDGFRp expression 
has been reported in the trachea and ureter (data not shown).
The analysis on the PDGFRp-LacZ line validated the suitability of the PDGFRp 
genomic fragment for SMC/pericyte specific expression. Subsequently, a PDGFRp-Cre 
construct was generated by inserting an IRES-Cre cassette into the PDGFRp genomic 
fragment as described before. A total of 13 transgenic founder lines were generated and 
tested in combination with the Rosa26R reporter line to assess Cre activity in embryos. 
Two functional lines were identified and the better of those, referred to as the PDGFRp- 
Cre, was used for all subsequent experiments. Stainings of E l 1.5 and E13.5 PDGFR[3- 
Cre/Rosa26R double transgenic embryos revealed high p-galactosidase expression in a 
wide range of vessels, similar to what has been seen for PDGFRp-LacZ mice (data not 
shown). Stained tissues and organs at E l8.5 included the mesenteric vessels in the 
intestine, vascular beds in the skin, and blood vessels and glomerular mesangial cells in 
the kidney (Figure 4.4). Some visceral SMC populations were also stained, such as the 
smooth muscle lining the stomach and the trachea (Figure 4.4).
4.2.3 Cell-type specificity of PDGFRp-Cre mice
The experiments described below were designed to determine whether PDGFRp-Cre 
expression is restricted to mural cell populations and excluded from the neighbouring 
endothelium.
4.2.3.1 Staining of the aorta
Aortas isolated from E18.5 embryos derived from timed matings between PDGFRp-Cre 
and Rosa26R mice, were assayed for P-gal activity. The stained tissue fragments were 
embedded in paraffin and sectioned. Cross-sections of the aorta revealed that the SMC 
layer was strongly lacZ positive while the monolayer of endothelial cells lining the 
lumen were devoid of blue staining (Figure 4.5a).
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Antibody stainings on aortic sections from an eight-week-old mouse that carried 
PDGFRp-Cre and Rosa26R alleles showed that a-Sm ooth Muscle Actin (a-SMA) 
antibody and p-galactosidase antibody were overlapping (Figure 4.5b). The vast 
majority of a-SM A cells express Cre recombinase.
4.2.3.2 RT-PCR analysis of isolated Cre-positive cells from skin
The gene expression profile of Cre-expressing cells from the PDGFRp-Cre mice were 
investigated by breeding to the RosaEYFP reporter line. This reporter leads to 
expression of Yellow Fluorescent Protein (YFP) as a result of Cre-mediated 
recombination (Srinivas et al., 2001). The RosaEYFP reporter enables easy visual 
monitoring of Cre activity without the need to stain. Embryos at E l 8.5 that contained 
both the PDGFRp-Cre and Rosa26EYFP alleles were identified under the ultraviolet 
light of the microscope by the yellow fluorescence in the skin. Fluorescent cells from 
the skin were isolated by Fluorescence-Activated Cell Sorting (FACS) and total RNA 
was extracted for the synthesis of cDNA and analysis by PCR. The RT-PCR indicated 
the presence of gene transcripts for the mural markers desmin and PDGFRp (Figure 
4,5c). While the endothelial marker PECAM-1 was absent from these cells, the 
receptors EphB2, EphB3 and EphB4 were also detected.
4.2.3.3 Genotyping on isolated endothelial cells from skin
Another approach used to determine whether the PDGFRp-Cre allele led to Cre 
expression in the endothelium was to look for evidence of recombination events in these 
cells. Aortas from eight-week-old adult PDGFRp-Cre mice, in an ephrinB2lox/+ 
heterozygous background, were isolated and cultured on collagen-coated dishes to 
induce sprouting. After 14 days, endothelial cells were isolated using Dynal beads 
coated with anti-PECAM-1 antibody and genotyped. This approach verified the 
presence of the intact loxP-flanked gene area and thereby the absence of Cre activity in 
the endothelium (Figure 4.5d).
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4.3 Discussion
Previous studies have shown ephrinB2 expression in vSMC of embryonic and adult 
mice (Shin et al., 2001). To investigate the role of ephrinB2 in these cells, and 
circumvent the early lethality of global embryos, mutants were generated using the 
Cre/loxP approach. For Cre expression in mural cells, SMMHC-Cre mice (Regan et al., 
2000) were characterised but this line showed only poor Cre expression in the embryo 
and was not suitable for further experiments. More recently, Frutkin and colleagues 
have reported similar problems with the SMMHC-Cre line, which in their hands, 
induced recombination in the parental germline but not in vSMCs (Frutkin et al., 2004). 
Therefore a new vSMC-specific Cre transgenic line was generated, in which expression 
of the recombinase is controlled by a fragment of the PDGFRp gene, which encodes a 
growth factor receptor found in SMCs and pericytes. With this strategy, several 
founders expressing Cre were generated and characterised by breeding to Rosa26R 
reporter mice. Specific staining in vSMCs at various embryonic stages and in adults 
indicated that the genomic PDGFRp fragment used for the generation of the transgenic 
line contained the regulatory elements required for expression in the vascular system. 
This is further supported by the fact that the PDGFRp-lacZ line displayed a similar 
expression pattern and argues against a major influence of the site at which the 
transgene was integrated into the genome.
As PDGFRp has been described to be present in SMC and pericytes and not in the 
endothelium in vivo, it appeared likely that the staining of blood vessels represented 
expression in mural cells. However, this requires further verification because the 
PDGFRp genomic fragment and the integration of the transgenic construct may have 
led to additional expression domains. Data presented here confirmed specific activity of 
the PDGFRp-Cre in mural and not endothelial cells as: a) only SMCs were positive in 
sections of stained aorta, b) immunofluorescent signals obtained with anti-p- 
galactosidase and anti-a-SM A antibodies were largely overlapping, c) RT-PCR on 
YFP-positive cells from skin contained transcripts for desmin and PDGFRp but not 
PECAM-1, and d) endothelial cells isolated from PDGFRp-Cre ephrinB2l0X/+ double 
heterozygotes contained an intact loxP-flanked allele. Although each of these 
experiments may have its own limitations, it is evident that PDGFRp-Cre expression in
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the vascular system is restricted to mural cell populations and absent in the 
endothelium. Next, this line was used in combination with conditional ephrinB2 mice to 
address the role of the ligand in pericytes and vascular smooth muscle cells.
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Figure 4.1: Generation of the PDGFRp-LacZ construct
A schematic diagram showing the cloning of the PDGFRp-LacZ construct. 
The IRES-LacZ cassette, also containing the SV40 pA signal at the 3' 
end, was inserted into exon 4 of the PDGFRp gene fragment, which 
included exons 3 to 6, as well as 6.2kb of upstream and 2.2kb of 
downstream intronic sequence.
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Figure 4.2: PDGFRf3-LacZ expression in embryos reveal staining in
vascular structures
The embryo at E11 was from transient transgenic experiments while the ones 
at E12 and E13.5 were generated from the stable line, p-galactosidas activity 
was detected in a wide range of vascular beds, such as the large vitelline 
vessel in the yolk sac (arrowhead), the anterior cardinal vein (asterisks), and 
intersomitic vessels (arrows).
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Figure 4.3: LacZ staining of blood vessel structures in different 
tissues/organs of PDGFRfJ-LacZ embryos at E18.5
p-galactosidase activity was evident in multiple tissues and organs of PDGFRp- 
LacZ embryos at E18.5. These included the mesenteric vessels leading into the 
intestine (arrowhead), glomeruli of the kidney (arrows), the vascular network in the 
meninges (asterisk) and vessel in the skin (open arrowheads). Specific staining 
was absent in the control littermates.
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Figure 4.4: LacZ staining of different tissues and organs from E18.5 PDGFRp- 
Cre and Rosa26R double transgenic embryos
Cre activity was detected in the vasculature of multiple tissues and organs including 
the mesenteric vessels leading into the intestine (arrowheads), kidney glomeruli 
(arrows), the vascular network in the meninges (asterisks), and the vasculature of 
the heart and stomach (open arrowheads). Visceral SMCs lining the stomach and 
trachea were also positive (open arrows). No staining was observed in the control 
tissues.
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Figure 4.5: PDGFRp-Cre transgenic express Cre selectively in mural cells
Staining of cross-sections through the aorta of PDGFRp-Cre mice in the Rosa26R 
background, p-galactosidase staining (a) was restricted to SMC layers (arrowhead) 
and absent from the endothelium lining the lumen (arrow). Double fluorescent 
labelling using a-SMA and p-galactosidase antibodies (b) reveal that lacZ 
expressing cells were also a-SMA positive. RT-PCR of Cre-positive cells from E18.5 
skin (MC) showing desmin and PDGFRp transcripts and absence of PECAM-1 
mRNA (c). The isolated cells were also positive for the receptors EphB2, EphB3 and 
EphB4. Positive control (+) reactions were performed on whole embryo cDNA. PCR 
on genomic DNA from two independent samples of endothelial cells isolated from 
aortic sprouts, revealed the presence of the intact ephrinB2lox allele (lox), i.e. the 
absence of Cre-mediated gene deletion (d), as well as the wildtype allele (wt).
SMA (3-gal
99
Chapter5
Chapters I Investigating the role of ephrinB2
in mural cells
5.1 Introduction
The results presented in the previous chapter and work by Gerety et al. (Gerety and 
Anderson, 2002) have shown that expression of ephrinB2 in endothelial cells is 
essential for normal blood vessel morphogenesis and angiogenic remodelling. In 
addition to the endothelium, mural cells in the embryonic and adult organism are 
another site of ephrinB2 expression at later stages of embryogenesis that persists into 
adulthood. Generation of PDGFR|3-Cre transgenics allowed the function of ephrinB2 in 
these cells to be addressed.
5.2 Results
5.2.1 Deletion of ephrinB2 in mural cells
Breeding of the PDGF|3-Cre mice into the ephrinB2 conditional background led to the 
generation of ephrinB2AMC mutants, that is, mice lacking the ligand in pericytes and 
vSMCs. These mutants developed to term but died shortly after birth, probably due to 
respiratory failure. EphrinB2AMC mutants exhibited oedema in the back region and 
widespread superficial haemorrhaging in the skin, which was particularly evident in the 
limb, head and dorsal area (Figure 5.1a-c). This phenotype is reminiscent of the 
appearance of PDGFRp (Figure 5.1d,e) and PDGF-B knockouts, but perhaps less 
severe. The excessive haemorrhaging in the ephrinB2AMC skin was detected as early as 
E l5.5 (data not shown).
Analysis of haematoxylin and eosin stained skin sections showed blood-filled vascular 
structures near the mutant epidermis (Figure 5.2a,b). Immunohistochemistry with the
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anti-PECAM-1 antibody, a marker for endothelial cells, revealed that capillaries in the 
ephrinB2AMC skin were dilated (Figure 5.2c,d).
EphrinB2AMC mutants display additional defects in the vascular beds of other organs. 
Freshly dissected intestines were pale and mesenteric lymphatic vessels were filled with 
erythrocytes, indicative of haemorrhaging (Figure 5.3a,b). Furthermore, sections 
revealed the presence of blood-filled lymphatics in the intestinal wall (Figure 5.3c,d). In 
mutant kidneys, “comma” and “S” shaped stages of the developing nephrons were 
normal. However, the appearance of more mature glomeruli was morphologically 
abnormal as indicated by dilated capillary tufts (Figure 5.3e,f). Alveoli in lungs were 
filled with blood cells (Figure 5.3g,h), which may explain the lethality of newborns.
5.2.2 Determining the expression of ephrinB2 and its receptor in the 
vasculature
Immunohistochemical staining of skin sections with anti-ephrinB2 antibody confirmed 
the absence of the ligand in arterial smooth muscle cells of large vessels in ephrinB2AMC 
mutants. Unexpectedly, ephrinB2 protein was undetectable in the adjacent arterial 
endothelial cells (Figure5.4a,b). Stainings with anti-EphB4 antibody revealed the 
venous endothelium in both mutants and controls (Figure 5.4c,d). Since the previous 
characterisation of the PDGFRp-Cre line showed no indication of Cre activity in 
endothelial cells, it is plausible that the inactivation of the gene in mural cells leads to 
the downregulated expression of ephrinB2 in the endothelium.
As shown in Figure 4.5c, several receptors for ephrinB2 are expressed in isolated mural 
cells. The spatial expression pattern of these molecules in the skin vasculature was 
characterised by antibody staining to identify potential sites of ephrinB2-EphB receptor 
interaction and signalling. EphrinB2 protein labelled the endothelium and the SMC 
layer of the large arterioles (Figure 5.5a). EphrinB2 levels were below the detection 
limit in smaller arterioles and in capillaries (Figure 5.5b,c). EphB4 signal was present in 
endothelial cells of both larger and smaller venules but absent in capillaries (Figure 
5.5d-f). Antibodies against EphB2 and EphB3 stained the mesenchyme surrounding 
both larger arterioles and venules as well as some vSMC (Figure5.5g,j). Both EphB2
101
Chapter5
and EphB3 were absent in SMC-coated vessels of smaller calibre and in capillary beds 
(Figure 5.5h,i,k,l).
Although microvessels in the skin are very sensitive to the effects of ephrinB2 deletion, 
immunohistochemistry failed to show expression of ephrinB2 or its receptors in the 
small calibre vasculature. Whole-mount lacZ staining was performed on various organs 
of E18.5 ephrinB2taulacZ embryos (Shin et al., 2001) to visualise the pattern of 
ephrinB2 promoter activity. This approach showed weak but specific staining in smaller 
vessels and capillary plexi of the meninges, skin and intestine, revealing the presence of 
ephrinB2 in these structures (Figure 5.6a-d). However, lacZ expression increased with 
vessel diameter and was most prominent on larger arterioles and arteries.
5.2.3 Normal patterning of the mutant vascular network
Inactivation of the ephrinB2 gene in the mural cells resulted in downregulated 
expression in the endothelium. Because endothelial ephrinB2 is required for 
angiogenesis in the early embryo, whether this reduction impairs the vascular 
architecture was investigated. EphrinB2AMC mutants were bred into the Tie21acZ 
background, a reporter expressing P-galactosidase in endothelial cells (Schlaeger et al., 
1997). Surprisingly, staining of the vascular network in the mesenteric vessels and skin 
of mutants at E l8.5, revealed no appreciable differences to controls (Figure 5.7a-d).
5.2.4 Normal mural cell numbers and distribution pattern in the larger 
vessel of mutants
To investigate whether the disruption of vascular integrity and haemorrhaging in the 
ephrinB2AMC mutants was caused by insufficient mural cell coverage, as is the case in 
mutant mice with a disrupted PDGFRj3 pathway, the line was bred into the X-lacZ 
background. This reporter line expresses lacZ in pericytes (Tidhar et al., 2001). As p~ 
galactosidase staining in these mice is confined to the nucleus, stained cells can be 
readily quantified. Analysis of different tissues including skin, mesentery, and the 
meninges showed no obvious differences between ephrinB2AMC mutants and littermate
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controls (Figure 5.8a-j). Quantification of stained cells in the vasculature in the 
meninges and skin indicated that the loss of the ephrinB2 gene has no impact on the 
number of X-lacZ positive cells in these tissues (Figure 5.9).
5.2.5 EphrinB2 is required for normal microvessel architecture
The data presented above shows that ephrinB2 ablation in mural cells does not affect 
their number and did not provide an explanation for the vascular defects in ephrinB2AMC 
mutants. Therefore, the microvessel architecture was investigated by whole-mount 
double immunofluorescence on skin. At the lower magnification (lOx), staining with 
antibodies detecting PECAM-1 and a-SM A  showed no obvious difference in the 
number of mutant vSMCs. Prominent a-SM A staining covered large arteries and veins 
of ephrinB2AMC mutants (Figure 5.10a,b). This was in strong contrast to the situation in 
PDGFRp knockouts, in which vSMC coverage was sparse on large vessels and absent 
in the microvascular network (Figure 5.10c). The analysis of ephrinB2AMC microvessels 
at the high magnification (63x) revealed that the spatial distribution of vSMCs was 
discontinuous and incomplete (Figure 5.10d,e). Moreover, many a-SMA-positive cells 
were rounded and poorly associated with the endothelium (Figure 5.10f,g). Double 
staining for PECAM-1 and the pericyte marker, desmin, showed that pericytes in 
control embryos were tightly wrapped around the abluminal surface of endothelial cells. 
In contrast, ephrinB2-deficient pericytes were poorly associated with the endothelium 
(Figure 5.11a-d) and appeared to protrude cellular processes away from vessels (Figure 
5.11d,e). Other pericytes displayed an abnormally round morphology and failed to 
envelope the capillaries (Figure 5.11f,g).
These findings were also confirmed by results at the ultrastructural level. Electron 
micrographs of skin microvessels confirmed that mutant pericytes made, were poorly 
associated with the endothelium (Figure 5.12a-d). An excessive number of collagen 
fibrils were seen in the extracellular matrix surrounding the mutant vessels and 
pericytes. Microvessels were dilated and some released erythrocytes due to ruptures in 
the endothelium (Figure 5.12e).
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5.2.6 Abnormal smooth muscle recruitment to ephrinl^^0 lymphatic 
capillaries
Anti-PECAM-l immunofluorescence allowed the visualisation of endothelial cells of 
lymphatics and blood vessels. Both vessel types can be distinguished in embryonic skin 
as the former have a significantly larger lumen. Lymphatic capillaries are normally 
devoid of smooth muscle cells whereas the lymphatic collecting ducts are covered to 
facilitate the transport of excess interstitial fluids and extravasated molecules into the 
venous circulation. Unexpectedly, lymphatic capillaries in ephrinB2AMC skin displayed 
abnormal recruitment of SMCs (Figure 5.13a-d). It was also observed that a subset of 
mutant vSMCs appeared to bridge blood vessels and lymphatics suggesting that they 
may move between vessels of a different type (Figure5.13e,f). Double staining with a -  
SMA and the lymphatic marker LYVE-1 verified that lymphatics had abnormal vSMC 
coverage (Figure 5.14a). These observations were confirmed by stainings of skin 
sections (Figure 5.14b,c). Due to the macroscopic similarities between PDGFR|3 
knockout (PDGFRp-KO) and ephrinB2AMC mice, PDGFR|3-KO skin samples were 
analysed by double stainings with a-SM A and LYVE-1 antibodies. This demonstrated 
that the inactivation of the PDGFRp gene also resulted in ectopic SMC recruitment to 
lymphatics (Figure 5.14d,e).
5.2.7 Isolation and immortalisation of vSMCs for in vitro studies
To study the effects of ephrinB2 inactivation in cultured cells, mouse smooth muscle 
cells were isolated and immortalised. This was achieved with the help of tsA58 in 
“immorto” mice, in which the expression of a temperature-sensitive version of the 
SV40 T-antigen can be induced by y-interferon. SMCs from cultured adult aorta 
fragments were isolated and immortalised and the identity of these cells was confirmed 
by a-SM A immunofluorescence (Figure 5.15a).
Lysates from immortalised SMCs were selected for glycoproteins with wheat germ 
agglutinin and the resultant solutes were loaded on SDS acrylamide gels for western
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blotting. The results confirmed the presence of ephrinB2 and its receptors EphB2, 
EphB3 and EphB4 in the cultured cells (Figure 5.15b,c).
5.2.8 Sprouting from ephrinBl^0 mice explants
To investigate whether the ablation of ephrinB2 in mural cells affects SMC sprouting 
and migration in response to PDGF-B, sprouting assays were performed. Aorta pieces 
were isolated from ephrinB2AMC mutants and cultured on collagen I-coated plates in 
medium supplemented with 20ng/ml of PDGF-B. Photographs taken after 48 hours 
showed that both control and mutant pieces cultured in the absence of PDGF-B 
displayed no SMC sprouting (Figure 5.16a and data not shown). Sprouting was only 
observed in a subset of mutant and control aorta fragments (Figure 5.16b,c). Subsequent 
analysis on the number of explants with sprouts revealed that ephrinB2AMC had lower 
success rates (15.4%) than controls (54.5%)(Figure 5.16d). This suggests that the loss of 
ephrinB2 may affect cell migration and sprouting.
5.3 Discussions
The generation of a mural cell-specific Cre transgenic line permitted the investigation of 
the role of ephrinB2 in pericytes and vSMCs. EphrinB2AMC mutants were generated by 
breeding the PDGFR|3-Cre line into the ephrinB2 conditional background. These 
mutants survived to term but died within minutes after birth. Embryos at E l8.5 
displayed oedema and widespread haemorrhaging in the skin that macroscopically 
resembled knockout mice lacking PDGF-B or PDGFRfk Further similarities with these 
mutants were locally dilated microvessels (microaneurysm) in the skin and the 
accumulation of blood in the lymphatic vessels of the mesentery. In ephrinB2AMC mice 
kidneys, glomeruli with abnormally dilated capillary tufts were observed. Similar 
defects were seen in the glomeruli of PDGF-B and PDGFRfl knockouts due to the 
reduced numbers of mesangial cells (Leveen et al., 1994; Soriano, 1994; Lindahl et al., 
1998; Hellstrom et al., 1999). However, unlike PDGF-B and PDGFRp knockouts, 
ephrinB2AMC mutants have normal numbers of pericytes and vSMCs in the affected 
tissues. More detailed analysis confirmed that ephrinB2-deficient mural cells are
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impaired in their ability to associate with microvessels. Therefore, ephrinB2 does not 
play an obvious role in mural cell proliferation or survival but is a mediator of cell-cell 
interactions and adhesion.
Attachment and investment defects are also characteristic of microvessels in the PDGF- 
B retention mutants, which express a truncated form of PDGF-B that is unable to bind 
matrix and form surface gradients (Abramsson et al., 2003). The diffusion of PDGF-B 
alters its spatial presentation so that the signal cannot be properly interpreted by mural 
cells. Although PDGF-B retention mutants are hypomorphic and mural cells are 
reduced due to lower PDGF-B levels, it is plausible that ephrinB2 could be in some way 
required for the cellular response to PDGF-B. This would also be consistent with the 
ectopic SMC coverage on skin lymphatics in both ephrinB2AMC and PDGFR|3-KO mice. 
PDGFRp signalling, in response to PDGF-B secreted by blood vessels, may prevent the 
ability of SMCs to colonise lymphatics. The ephrinB2AMC phenotype may well indicate a 
role of Eph-ephrin interactions in this process.
Based on the expression analysis described above, ephrinB2 is most likely to engage 
EphB receptors on vessels of large diameter, i.e. those vessels that have the most 
extensive mural cell coverage. As ephrinB2 and EphB levels decrease with vessel 
diameter, one would predict only low, yet potentially important, interactions within the 
microvasculature. The mutant phenotype suggests that such interactions would 
presumably enhance cell-cell contacts and attachment. Alternatively, gradients of 
Eph/ephrin molecules along vessels may promote cell migration and ensure the correct 
spacing of mural cells. This scenario may involve repulsive sorting signals.
The ablation of ephrinB2 in mural cells also resulted in downregulated expression in 
arterial endothelial cells. The mechanism underlying these changes is unclear but may 
involve direct regulation by Eph-ephrin signalling. Alternatively, other signals, 
provided by secreted factors or matrix, may control the expression of Eph-ephrin 
molecules in the vasculature. Whatever the mechanism, it is remarkable that the 
reduction of endothelial ephrinB2 expression remains without consequences for 
angiogenic remodelling. This finding suggests that the function of ephrinB2 shifts from 
angiogenesis to mural cell recruitment during development.
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Figure 5.1: Vascular defects in ephrinB2AMC mutants at E18.5
Freshly dissected E18.5 ephrinB2AMC embryos from two different litters show 
severe haemorrhaging in skin of the limbs (b,c, open arrowheads), back (b, 
arrowhead) and head (c, arrowhead) which was absent in littermate 
controls (a). Haemorrhaging is also a prominent feature in PDGFRp 
knockout embryos at the same stage (d,e).
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Figure 5.2: Ablation of ephrinB2 in mural cells leads to 
microaneurysms in the skin
Haematoxylin and eosin (H & E) staining of ephrinB2AMC skin sections at 
E18.5 showing that vascular structures near the epidermis (Ep) were 
severely dilated and filled with blood cells (b, arrows). Capillaries, which 
are labelled for the EC marker PECAM-1, are dilated in ephrinB2AMC skin 
(d, arrowheads). The nuclei were counter-stained with 4,6-diamidino-2- 
phenylindole (DAPI). Control sections are shown in (a) and (c).
Control ephrinB2AMC
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Figure 5.3: Vascular defects in ephrinB2AMC mutants
Freshly dissected intestine of mutants were pale and the mesenteric 
lymphatics were filled with blood (b, arrow). H & E stainings of 
ephrinB2AMC intestinal sections showed large blood-filled vascular 
structures (d, arrow). Mutant glomeruli displayed abnormal dilation of 
the capillary tuft (f, arrow). Blood occupied the alveolar spaces in the 
mutant lung. These defects were not seen in the littermates control 
samples (a, c, e and f).
Control ephrinB2AMC
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Figure 5.4: The deletion of ephrinB2 in mural cells causes the loss of the
ligand in ECs
Double immunofluorescence with antibody against PECAM-1 and a-SMC on 
embryonic skin sections confirming the presence of ephrinB2 in both arterial 
SMCs (a, arrow) and ECs (a, arrowhead) of controls. In the ephrinB2AMC 
mutants, ephrinB2 was absent in both cell types as the remaining green 
fluorescence is background signal (b). Green and red channels and merged 
images are shown. EphB4 was expressed in venous ECs of both controls and 
mutants (c,d). Nuclei staining (DAPI) is shown in blue.
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Figure 5.5: Expression of ephrinB2 and EphB receptors in blood vessels of
the skin
Immunofluorescence with specific antibodies directed against ephrinB2, EphB4, 
EphB2, and EphB3 (green) in combination with a-SMA stainings (red) on 
consecutive sections from E18.5 skin. Arteries are denoted by (A) and veins by (V), 
while PECAM-1 (green) was used to stain capillaries (C) in (m). In larger vessels, 
ephrinB2 signal labels the endothelium and SMCs of the artery, EphB4 the venous 
endothelium, EphB2 and EphB3 the mesenchyme surrounding the vessels and a 
subset of the SMCs (a,d,g,j respectively). In the smaller vessels ephrinB2, EphB2 
and EphB3 (b,h,k) are undetectable, while EphB4 is visible in the vein (e). 
Capillaries were negative for ephrinB2 and the three receptors (c,f,i,l). Nuclei are 
shown in blue (DAPI).
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Figure 5.6: EphrinB2 expression in smaller vessels and capillaries
LacZ stainings of tissues from ephrinB2taulacZ heterozygous embryos 
at E18.5. p-galactosidase is most prominent in larger vessels but 
weaker signals extend into the microvessels.
112
Control
Figure 5.7: Normal patterning of the ephrinB2AMC endothelium
Freshly dissected tissues from E18.5 embryos in a Tie2lacZ 
background were assayed for p-galactosidase activity. Staining 
revealed no appreciable differences between mutant and control 
vasculature in skin (a,b) and mesentery (c,d). Mesenteric blood vessel 
are indicated by arrows and accumulated blood cells in mutant 
lymphatics by an arrowhead (d).
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Figure 5.8: Normal mural cell numbers and in distribution pattern 
in the larger vessels of m utants
Freshly dissected tissues and organs from E18.5 embryos in a X-lacZ4 
background were assayed for |3-gal activity labelling pericytes. The 
number and spatial distribution of the X-lacZ4 positive mural cells was 
similar in the vascular beds of the skin of the skin (a-d), intestinal 
mesentery (e,f), and meninges (g-j).
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Figure 5.9: Quantification of mural cell numbers in m utants and controls
The number of mural cells were quantified in four fields of each sample type. 
The result revealed no significant differences between the mutant and control 
samples. Standard of deviations are indicated by error bars.
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Figure 5.10: The ablation of ephrinB2 in mural cells results in abnormal
microvessel architecture
Whole-mount immunofluorescence with antibodies against a-SMA (green) 
and PECAM-1 (red) on skin of E18.5 embryos. At low magnification, the 
overall organisation of the mutant vasculature appeared comparable to 
controls and large vessels had robust SMC coverage (a,b). In PDGFRp-KO 
skin, vSMCs was sparse even on larger vessels (c). At high magnification, 
vSMC distribution in the mutant microvasculature appeared patchy and 
incomplete (d,e). Stained cells had abnormally round shapes and did not 
ensheath the endothelium (f,g, arrows).
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Figure 5.11: Pericytes failed to envelope the vessels and make 
proper associations with the endothelium in mutants
Immunofluorescence on skin paraffin sections (a,b) and whole-mounts (c- 
g) with desmin (green) and PECAM-1 (red) antibodies. Images at 63x 
magnification revealed that mutant pericytes were loosely connected to 
the endothelium (a-d, arrows) and were stretching away from vessels 
(d,e, arrows). Other pericytes were abnormally round and failed to wrap 
around the PECAM-1 positive endothelium (f,g, arrows).
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Figure 5.12: Mutant pericytes failed to form proper associations with
the endothelium
Electron micrographs showing impaired interaction between pericytes (P) 
and endothelial cells (EC) of mutants (b,d) in contrast to controls (a,c). Note 
that the extracellular matrix surrounding ephrinB2AMC vessels contains more 
collagen fibres (open arrows). Poor pericyte association leads to vessel 
dilation, rupture and the release of blood cells into the surrounding tissue (e).
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Figure 5.13: Abnormal SMC recruitment to capillary lymphatic vessels in
ephrinB2AMC mutants
Whole-mount immunofluorescent staining of E18.5 skin with a-SMA (green) and 
PECAM-1 (red) antibodies. Blood vessels are denoted by (B) and lymphatics by 
(L). Images taken at a magnification of 10x showed ectopic SMC coverage of 
lymphatic capillaries in mutants (b, arrowheads) but not in controls (a). Ectopic 
SMC coverage was extensive in some regions (c,d). Some a-SMA-positive cells 
seemed to cross from blood vessels to adjacent lymphatics (e,f, arrow).
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Figure 5.14: Abnormal SMC recruitment to lymphatic capillaries in 
ephrinB2AMC mutants and PDGFRp null mice
Immunofluorescence of E18.5 skin whole-mounts (a,d) and paraffin sections 
(b,c,e). Images were taken at 40x magnification. Co-stainings of LYVE-1 (green) 
and a-SMA (red) confirmed that SMCs covered lymphatic capillaries in the 
ephrinB2AMC mutant (a, arrows). SMC recruitment to lymphatics (arrow) was also 
visible in skin sections (c, arrows) and absent in control (b). Similar ectopic SMC 
coverage of lymphatics (arrows) was evident in PDGFRp-KO skin samples (d,e, 
arrows).
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Figure 5.15: Immortalised vSMCs express ephrinB2 and
EphB receptors
a-SMA-positive cultured cells that were isolated from from aortic 
fragments (a). Western Blot (WB) showing expression of 
ephrinB2 (b) as well as EphB2, EphB3 and EphB4 receptors (c), 
in immortalised SMCs. Embryo lysates was used as positive 
control (b).
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Number of aortic pieces that 
sprouted in the presence of PDGF-B
12 2
Total number of aortic pieces 22 13
54.5% 15.4%
Figure 5.16: Aortic pieces from ephrinB2AMC showed less sprouting in the
presence of PDGF-B
Images taken of aortic pieces in culture after 48 hours, in the absence/presence 
of PDGF-B (20ng/ml) as indicated. In the absence of PDGF-B, no sprouting from 
the aortic explants was observed (a). In the presence of PDGF-B, a fraction of 
both mutant and control samples displayed sprouting from explants (b,c). 
However, the number of sprouting mutant explants was lower in comparison to 
controls (d).
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Chapter6 I Discussion & concluding remarks
6.1 General Overview
The vascular network is the first functional system to develop in the embryo and 
ensures that adequate blood flow provides tissues with a sufficient supply of nutrients 
and oxygen and removes waste products and carbon dioxide. The formation of this 
functional blood vessel network is initiated by “vasculogenesis”, a process in which 
angioblasts proliferate and coalesce into a primitive network of vessels known as the 
primitive capillary plexus (Carmeliet et al., 1998). The endothelial cell lattice created by 
vasculogenesis then serves as a scaffold for angiogenesis, which is the remodelling of 
the network into a hierarchically organised vasculature. This process involves extensive 
changes in the cell-cell and cell-ECM interactions in response to signals by precisely 
balanced angiogenic stimulators and inhibitors (Carmeliet, 2000). Angiogenesis occurs 
mostly during embryonic development, to address the increasing demands of tissues and 
organs. In contrast, the adult vasculature is stable and there is very little turnover of 
endothelial cells. Angiogenesis in adult organisms is confined to physiological wound 
healing processes and the menstruation cycle but is also a hallmark of many 
pathological conditions such as proliferative diabetic retinopathy and tumour 
neovascularisation (Papetti and Herman, 2002).
Over the past few years, several studies have demonstrated the essential role of 
ephrinB2 in the developing vascular system, where its early expression is restricted to 
the endothelial cells of the arterial, but not venous blood vessels (Wang et al., 1998). 
EphrinB2 null mutant mice are lethal at midgestation due to severe malformation of the 
vasculature including the lack of angiogenic remodelling. Similar defects occurred in 
EphB4 deficient mice and in a subset of mice lacking the two receptors EphB2 and 
EphB3 (Adams et al., 1999; Gerety et al., 1999). As these are binding partners for 
ephrinB2, it suggests that the ephrinB2 activation of reciprocal receptor-ligand 
interactions and the downstream signal transduction cascades appear to be essential for 
normal blood vessel formation. Although the role of the ephrinB2 cytoplasmic domain, 
in the process of vascular morphogenesis, is controversial, several studies have been
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shown that ephrins have active, receptor-like signalling functions (Bruckner et al., 1999; 
Lu et al., 2001; Song, 2003). The cytoplasmic domain may be also involved in 
conformational alterations, protein stability, intracellular translocation, membrane 
presentation, internalisation and recycling, but such functions remain to be addressed.
Two studies have shown that ephrinB2 expression progressively extends from the 
arterial endothelium to surrounding arterial smooth muscle cells and pericytes, during 
late embryogenesis (Gale et al., 2001; Shin et al., 2001). This arterial pattern persists 
into adults but the ligand is also upregulated in settings of physiological and 
pathological angiogenic processes. The observation that ephrinB2 is essential for 
angiogenesis in the early embryo and expression patterns in the adult suggest that the 
ligand may modulate blood vessel remodelling in a wide range of settings. Moreover, 
the expression of ephrinB2 in SMCs and pericytes hint at an involvement in 
endothelial-mural cell interactions.
6.2 The role of ephrinB2 in endothelial cells
The early lethality of ephrinB2 null mutants is a major obstacle for functional studies 
during later stages of vascular morphogenesis. Moreover, it has not been possible to 
address the role of ephrinB2 in specific cell types. A genetic approach in mice, using 
the Cre-loxP system, has been employed to overcome these limitations. To determine 
the role of ephrinB2 in endothelial cells, the transgenic Tiel-Cre line was bred into a 
background of ephrinB2lox mice. The resulting ephrinB2AEC mutants exhibited defects in 
angiogenic rem odelling, cardiac m alform ations and lethality rem iniscent of 
conventional ephrinB2 knockouts. These findings indicate that ephrinB2 expression in 
endothelial and endocardial cells is essential for the principle steps of cardiovascular 
development. EphrinB2 in other cell populations or other B-class ephrins are unable to 
compensate for these defects. As the Tiel-Cre is expressed in both endothelial and 
endocardial cell lineages, the question remains open whether some of the vascular 
defects in ephrinB2AEC mutants are caused by cardiac malfunction and the resulting 
haemodynamic changes.
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The early lethality of the ephrinB2AEC mutants did not permit and functional studies 
during late embryogenesis or in adults. To control the time course of EC-specific gene 
inactivation, the Tie2-CreERT transgenic was characterised to explore its suitability for 
functional studies. A first series of experiments suggested the line permitted only poor 
Cre-mediated recombination in embryos, adults and tumours treated with tamoxifen. 
These problems were probably caused by technical difficulties in the solubilisation of 
tamoxifen and 40H-TM  and recent results have shown significant improvements when 
applying a modified protocol. This may now permit EC-specific inactivation of 
ephrinB2 during various stages of development. Alternatively, other tamoxifen- 
controlled Cre lines or different inducible systems may be employed for the same 
purpose.
6.3 EphrinB2 function in mural cells
The successful generation and characterisation of PDGFR|3-Cre mice permitted the 
generation of mural cell-specific ephrinB2 mutants, ephrinB2AMC. These mice develop 
to term but died shortly after birth, presumably due to respiratory failure. EphrinB2AMC 
embryos exhibited oedema and widespread haemorrhaging in the skin, which was 
particularly evident in the limb, back and head regions, reminiscent of the PDGF-B and 
PDGFRp null phenotypes (Soriano, 1994; Hellstrom et al., 1999). Other defects 
included haemorrhaging in the lymphatics of the mesentery and intestine, dilation of the 
capillary tufts in the glomeruli and blood-filled alveolar spaces in the lungs.
Immunohistochemistry on mutant skin showed that the ablation of ephrinB2 in mural 
cells led to downregulated ephrinB2 expression in the endothelium of larger arterioles 
in the skin. It remains unclear whether a similar downregulation occurs in the 
endothelium of smaller arterioles and in microvessels, because neither the expression of 
ephrinB2 nor EphB receptors were detectable by antibody stainings in these structures. 
This could be due to the detection limitations of the antibodies as well as low or absent 
ephrinB2 protein. Nevertheless, lacZ staining of multiple tissues from ephrinB2tauLacZ 
mice has indicated at least some ephrinB2 expression in the small calibre vessels. 
Cross-breeding of ephrinB2tauLacZ mice and PDGFR|3-Cre/ephrinB2Iox/+ double
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heterozygotes will allow the study of the regulation of ephrinB2 expression in a more 
conclusive manner.
Despite the downregulation of endothelial ephrinB2 in mutant arterioles, it is 
remarkable that embryos survive until birth. Moreover, P-galactosidase staining under 
the control of the Tie21acZ reporter, indicated that the overall organisation of the mutant 
blood vessel network was surprisingly normal. This observation is in stark contrast to 
the severe vascular defects seen in ephrinB2 and EphB4 null mice, as well as in 
ephrinB2AEC mutants. Thus, ephrinB2 expression in the endothelium may be only 
essential during the early stages of vascular morphogenesis and later critical functions 
may shift from the endothelium to mural cells. This coincides with progressively 
increasing ephrinB2 expression in these cell types.
Quantification of mural cells in a X-lacZ4 reporter background and antibody staining 
indicated that the number of mural cells in mutants was comparable to control embryos. 
However, characterisation of the mutant microvasculature indicated that the association 
of SMCs and pericytes with the endothelium was compromised. Mural coverage of the 
microvessels was discontinuous and incomplete. Furthermore, mutant pericytes failed to 
attach properly to the endothelium. Because Eph receptors and ephrins can mediate 
adhesion as well as repulsive interactions during development (Murai and Pasquale, 
2003), the loss of ephrinB2 may lead to adhesion defects without appreciable 
consequences for mural cell proliferation and survival. However, the expression levels 
for ephrinB2 protein and its receptor are highest on vessels of larger calibre and 
decreases with vessel diameter. This suggests that a gradient of ephrinB2 may help to 
establish a stable vessel wall, perhaps by controlling mural cell guidance and/or 
adhesion. Previous work has also shown that the co-expression of ephrin ligands can 
mask Eph receptors in the same cells and thereby modulate cell-cell interactions and 
signalling (Homberger et al., 1999). The characterisation of isolated vSMCs suggests 
that ephrinB2 may mask the co-expressed receptors EphB2, EphB3 and EphB4 in a 
similar fashion. Preliminary results suggest that the binding of soluble ephrinB2/Fc 
protein to cultured ephrinB2-deficient SMCs is increased, i.e. that more receptors have 
become available for interaction with other cells (data not shown). In this setting, mural
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ephrinB2 may modulate repulsive signals, that is, Eph receptor activation by ligands 
presented by endothelial cells and adjacent pericytes/vSMCs.
Irrespective of the adhesive or repulsive nature of the underlying mechanism, mutant 
microvessels are not sufficiently supported by mural cells, which lead to their dilation 
and eventual rupture. The presence of blood-filled lymphatics in skin and intestine may 
be secondary to the haemorrhaging seen in these tissues.
The data provided here, introduces the conundrum of why the association of mural cells 
to the wall of larger and intermediate-size vessels appears to be normal, while only the 
m icrovessels are affected in the mutants. In contrast to the defect in mutant 
microvessels, larger vessels manage to maintain their stability and it is plausible that 
other molecules are able to compensate for the loss of ephrinB2 in these pericytes and 
vSMC populations. Mature vessels with robust SMC coating may not be susceptible to 
perturbations caused by the loss of ephrinB2. In the microvasculature, where angiogenic 
sprouting is still taking place and mural cell coverage is incomplete, vessels are more 
prone to destabilisation and may therefore require intact Eph-ephrin interactions. The 
fact that the rupture of blood vessels was only seen to have occurred at later stages of 
embryonic development indicates that ephrinB2 may not have the same essential role in 
earlier steps of vascular morphogenesis.
To acquire a more complete understanding of the role of ephrinB2 in mural cells, 
several issues need to be addressed. It will be important to understand whether the 
engagement and activation of Eph receptors is required for the stabilisation of 
microvessels. Furthermore, ligand cleavage or the internalisation of the ligand-receptor 
complex may play a critical role. Conditional ephrinB2 mice could be also used to study 
the origin of SMCs in different vascular beds. Such work is limited by a lack of markers 
for the precursors of pericytes and vSMCs. One possible experiment may be to breed 
the ephrinB2 conditional line into the W ntl-Cre background. As the W ntl-Cre is neural 
crest cell (NCC) specific (Danielian et al., 1998; Brewer et al., 2004), the ephrinB2 
gene would be inactivated in SMCs above the thoracic, i.e. in those cells that are 
derived from NCC progenitors. Consequently, these mutants may develop vascular 
defects and haemorrhaging in the head region.
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EphrinB2AMC mice display phenotypic similarities to mutants in the PDGF-B/PDGFRp 
pathway (Soriano, 1994; Hellstrom et al., 1999). In particular, ephrinB2AMC mutants and 
PDGF-B retention mutants both showed impairment of pericyte investment in the 
microvessel wall (Lindblom et al., 2003). As the PDGF-B retention mutants express a 
truncated form of PDGF-B that cannot be retained by binding to the extracellular 
matrix, this impairs its normal presentation sites and disrupts gradients essential for the 
proper recruitment of mural cells. Overexpression of PDGF-B in tumours grown in 
PDGF-B retention mutants led to an increase in pericyte numbers but failed to rescue 
recruitment and investment defects (Abramsson et al., 2003).Thus, the precise 
presentation of the PDGF-B signal is essential to establish functional mural-endothelial 
interactions. The levels of PDGFR|3 expression in ephrinB2AMC vSMCs appear normal 
(data not shown) and preliminary work from the laboratory suggests that ephrinB2 may 
modulate the cellular response to PDGF-B. Previous work has shown that activated 
PDGF receptor can induce the phosphorylation of tyrosine residues in the cytoplasmic 
domains of the B-class ephrins (Bruckner et al., 1997). Future work will address the 
biological relevance of this observation and explore the possibility of a direct link 
between the two pathways.
6.4 Ectopic recruitment of SMCs to lymphatics capillaries
Another feature of the ephrinB2AMC mutants is the ectopic recruitment of SMCs to the 
lymphatic capillary beds of the skin. Lymphatics remove excess interstitial liquid and 
extravasate molecules and drain into veins. This function requires that lymphatic 
endothelial cells can open intercellular gaps as well as the absence of mural cells. 
Abnormal SMC coverage and constriction of lymphatics in FOXC2 mutant mice and in 
human patients suffering from lymphedema distichiasis, leads to lymphedema (Petrova 
et al., 2004). It has been shown that this SMC recruitment is caused by ectopic 
expression of PDGF-B in lymphatic capillaries. Indicative of some sort of link of 
unknown nature between ephrinB2 and the PDGFR|3 pathway, PDGFRfJ knockout mice 
also showed SMCs on skin lymphatics despite the dramatic reduction of vascular 
smooth muscle coverage. Surprisingly, PDGF-B retention mutants or PDGF-B nulls did 
not phenocopy this defect and their lymphatic capillaries remained free of vSMCs. This 
indicates that other factor, perhaps the related PDGF-D molecule, might compensate for
128
Chapter6
the loss of PDGF-B, although to a limited extent. It also shows that SMC recruitment to 
distal lymphatics is not a secondary response to oedema but is caused by specific 
molecular defects. The relevant molecular signals remain to be investigated, but ectopic 
PDGF-B secretion by lymphatic capillaries in ephrinB2AMC mutants may attract mural 
cells, like in the FOXC2-deficient mice. Alternatively, the absence of ephrinB2 in mural 
cells may eliminate repulsive signals that prevent attachment to EphB4-expressing 
lymphatics (data not shown). To address the precise mechanism of how ephrinB2 
mediates proper assembly of the mural cells to the microvessels as well as ectopic SMC 
coverage in the lymphatics in its absence, it will be important to understand the 
repulsive or attractive nature of EphB-ephrinB2 interactions in the vascular system.
6.5 Which pathways may be involved in the ephrinBZ^0 
phenotype?
Besides the possible role of PDGFJ3 discussed above, other molecular signals may be 
directly linked to the ephrinB2 function in pericytes and vSMCs. Electron micrographs 
from ephrinB2AMC mutant skin show excessive collagen fibrils around microvessels. 
Thus, ECM remodelling appears to be directly or indirectly involved , as a consequence 
of impaired mural cell-EC association in ephrinB2AMC mutants. Metalloproteases are key 
mediators of ECM remodelling, with functions ranging from the proteolytic cleavage of 
growth factors, ECM degradation, to the cleavage of cell-surface proteins (Chang and 
Werb, 2001). At this point, it is conceivable that the function of matrix metalloproteases 
(MMPs), metalloprotease-disintegrins (ADAMs) or natural tissue inhibitors of 
metalloproteases (TIMPS), may be altered in ephrinB2AMC mutants.
Previous studies have linked ephrins to integrin-mediated cell migration and adhesion. 
EphrinBl can transduce signals that activate integrin-mediated migration, attachment 
and angiogenesis in Chinese hamster ovary (CHO) cells (Huynh-Do et al., 2002). 
EphrinAl can block integrin-mediated vascular smooth muscle cell spreading via the 
Rac/PAK pathway (Deroanne et al., 2003). Integrins regulate cell-matrix and cell-cell 
interactions as well as motility function, roles that may contribute to the ephrinB2AMC 
phenotype.
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TGF-P signalling controls a range of cellular responses in endothelial cells and mural 
cells that affect their function (Goumans et al., 2003). These signals can be either 
stimulatory or inhibitory depending on the presence of additional cues. Several 
members of the TGF-|3 family have been implicated in the regulation of angiogenesis 
(Pepper, 1997; Goumans et al., 2003). Nevertheless, a connection of TGF-P molecules 
to Eph/ephrin signalling remains to be established.
Members of the Sphingosine-1 phosphate (SIP) family are also regulators of embryonic 
angiogenesis and blood vessel maturation, through the generation of knockouts (Kono 
et al., 2004). It has been suggested that ephrinAl can act in synergy with S IP  to 
destabilise blood vessels in early steps of angiogenesis (Deroanne et al., 2003). A role 
of SIP-induced signalling pathways in ephrinB2AMC mutants is currently not supported 
by direct evidence.
A challenge in the identification of the molecular mechanism underlying the defects in 
the ephrinB2AMC mutants, will be the separation of primary factors from secondary 
processes caused by haemorrhaging and oedema.
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6.6 Concluding remarks
The work presented here demonstrates that endothelial ephrinB2 expression is essential 
for angiogenesis and blood vessel development. Endothelial cell-specific ephrinB2 
deficiency leads to defects in angiogenic remodelling and cardiac malformations. This 
shows that endothelial ephrinB2 is indispensable for angiogenesis in early embryonic 
development and it will be important to investigate similar roles in a number of 
physiological and pathological settings.
In addition, my work shows that ephrinB2 is not only a critical regulator of 
angiogenesis but also involved in mural cell recruitment and vessel wall assembly. It 
has been previously shown that ephrinB2 expression progressively extends from the 
arterial endothelium to surrounding SMCs and pericytes (Gale et al., 2001; Shin et al., 
2001), but the functional significance of this process has remained unclear. Mural cell- 
specific deletion of ephrinB2, leads to impaired mural-endothelial interaction, loss of 
blood vessel integrity and, consequently, haemorrhaging and oedema.
Future work will address whether ephrinB2 is involved in human disease conditions 
with similar vascular defects, for example diabetic retinopathy, or in the disorganised 
morphology of tumour blood vessels. This will also be an important step in determining 
whether ephrinB2 might be a target for pro- or anti-angiogenic therapies or relevant in 
cardiovascular disorders.
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